<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-832-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RENVELA 800 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEVELAMER CARBONATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        800
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        180
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        623.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GENZYME IRELAND LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GENZYME IRELAND LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENZYME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AE02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Renvela contains sevelamer carbonate as the active substance. It binds phosphate from food in the digestive tract and so reduces serum phosphorus levels in the blood.<br />This medicine is used to control hyperphosphataemia (high blood phosphate levels) in:<br />&bull; adult patients on dialysis (a blood clearance technique). It can be used in patients undergoing haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood);<br />&bull; patients with chronic (long-term) kidney disease who are not on dialysis and have a serum (blood) phosphorus level equal to or above 1.78 mmol/l.<br />This medicine should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.<br />Increased levels of serum phosphorus can lead to hard deposits in your body called calcification. These deposits can stiffen your blood vessels and make it harder for blood to be pumped around the body. Increased serum phosphorus can also lead to itchy skin, red eyes, bone pain and fractures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Contraindications:</u><br />Do not take Renvela if:</strong><br />&bull; you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6).<br />&bull; you have low levels of phosphate in your blood (your doctor will check this for you)<br />&bull; you have bowel obstruction<br /><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Renvela if any of the following applies to you:<br />&bull; swallowing problems. Your doctor can rather prescribe Renvela powder for oral suspension<br />&bull; problems with motility (movement) in your stomach and bowel<br />&bull; being sick frequently<br />&bull; active inflammation of the bowel<br />&bull; have undergone major surgery on your stomach or bowel<br />Talk to your doctor while taking Renvela:<br />&bull; if you experience severe abdominal pain, stomach or intestine disorders, or blood in the stool (gastrointestinal bleeding). These symptoms can be due to serious inflammatory bowel disease caused by sevelamer crystals deposit in your bowel. Contact your doctor who will decide on continuing the treatment or not.<br />Additional treatments<br />Due to either your kidney condition or your dialysis treatment you may:<br />&bull; develop low or high levels of calcium in your blood. Since this medicine does not contain calcium your doctor might prescribe additional calcium tablets.<br />&bull; have a low amount of vitamin D in your blood. Therefore, your doctor may monitor the levels of vitamin D in your blood and prescribe additional vitamin D as necessary. If you do not take multivitamin supplements you may also develop low levels of vitamins A, E, K and folic acid in your blood and therefore your doctor may monitor these levels and prescribe supplemental vitamins as necessary.<br />&bull; have disturbed level of bicarbonate in your blood and increased acidity in the blood and other body tissue. Your doctor should monitor the level of bicarbonate in your blood.<br />Special note for patients on peritoneal dialysis<br />You may develop peritonitis (infection of your abdominal fluid) associated with your peritoneal dialysis. This risk can be reduced by careful adherence to sterile techniques during bag changes. You should tell your doctor immediately if you experience any new signs or symptoms of abdominal distress, abdominal swelling, abdominal pain, abdominal tenderness, or abdominal rigidity, constipation, fever, chills, nausea or vomiting.<br /><strong><u>Children</u></strong><br />The safety and efficacy in children (below the age of 6 years) have not been studied. Therefore this medicine is not recommended for use in children below the age of 6 years.<br /><strong>Other medicines and Renvela</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&bull; Renvela should not be taken at the same time as ciprofloxacin (an antibiotic).<br />&bull; If you are taking medicines for heart rhythm problems or for epilepsy, you should consult your doctor when taking Renvela.<br />&bull; The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used to suppress the immune system) may be reduced by Renvela. Your doctor will advise you if you are taking these medicines.<br />&bull; Thyroid hormone deficiency may uncommonly be observed in certain people taking levothyroxine (used to treat low thyroid hormone levels) and Renvela. Therefore your doctor may monitor the levels of thyroid stimulating hormone in your blood more closely.<br />&bull; Medicines treating heartburn and reflux from your stomach or oesophagus, such as omeprazole, pantoprazole, or lansoprazole, known as &ldquo;proton pump inhibitors&rdquo;, may reduce the efficacy of Renvela. Your doctor may monitor the phosphate level in your blood.<br />Your doctor will check for interactions between Renvela and other medicines on a regular basis.<br />In some cases where Renvela should be taken at the same time as another medicine. Your doctor may advise you to take this medicine 1 hour before or 3 hours after Renvela intake. Your doctor may also consider monitoring the levels of that medicine in your blood.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.<br />The potential risk of Renvela during human pregnancy is unknown. Talk to your doctor who will decide if you can continue the treatment with Renvela.<br />It is unknown whether Renvela is excreted in breast milk and may affect your baby. Talk to your doctor who will decide if you can breastfeed your baby or not, and if it is necessary to stop Renvela treatment.<br /><strong>Driving and using machines</strong><br />Renvela is unlikely to affect your ability to drive or to use machines.<br /><strong>Excipients</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must take Renvela as prescribed by your doctor. They will base the dose on your serum phosphorus level.</p><p>The recommended starting dose of Renvela tablets for adults and elderly is one to two tablets of 800 mg with each meal, 3 times a day. Check with your doctor, pharmacist or nurse if you are not sure.<br />Take Renvela after your meal or with food.<br />The tablets must be swallowed whole. Do not crush, chew or break into pieces.<br />Initially, your doctor will check the levels of phosphorus in your blood every 2-4 weeks and may adjust the dose of Renvela when necessary to reach an adequate phosphate level.<br />Follow the diet prescribed by your doctor.<br /><strong>If you take more Renvela than you should</strong><br />In the event of a possible overdose you should contact your doctor immediately.<br /><strong>If you forget to take Renvela</strong><br />If you have missed one dose, this dose should be omitted and the next dose should be taken at the usual time with a meal. Do not take a double dose to make up for a forgotten dose.<br /><strong>If you stop taking Renvela</strong><br />Taking your Renvela treatment is important to maintain an appropriate phosphate level in your blood. Stopping Renvela would lead to important consequences such as calcification in the blood vessels. If you consider stopping your Renvela treatment, contact your doctor or pharmacist first.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Constipation is a very common side effect (may affect more than 1 in 10 people). It can be an early symptom of a blockage in your intestine. In case of constipation, please inform your doctor or pharmacist.<br />Some side effects could be serious. If you get any of the following side effects, seek immediate medical attention:<br />- Allergic reaction (signs including rash, hives, swelling, trouble breathing). This is a very rare side effect (may affect up to 1 in 10,000 people).<br />- Blockage in the intestine (signs include: severe bloating; abdominal pain, swelling or cramps; severe constipation) has been reported. Frequency is not known (frequency cannot be estimated from the available data).<br />- Rupture in the intestinal wall (signs include: severe stomach pain, chills, fever, nausea, vomiting, or a tender abdomen) has been reported. Frequency is not known.<br />- Serious inflammation of the large bowel (symptoms include: severe abdominal pain, stomach or intestine disorders, or blood in the stool [gastrointestinal bleeding]) and crystal deposit in the intestine have been reported. Frequency is not known.<br />Other side effects have been reported in patients taking Renvela:</p><p><u>Very common:</u><br />vomiting, upper abdominal pain, nausea<br /><u>Common </u>(may affect up to 1 in 10 people):<br />diarrhoea, stomach ache, indigestion, flatulence<br /><u>Not known:</u><br />cases of itching, rash, slow intestine motility (movement)<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />The National Pharmacovigilance Centre (NPC):<br />o SFDA call center : 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date stated on the bottle and carton after the letters &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Keep the bottle container tightly closed in order to protect from moisture.<br />Do not store above 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is sevelamer carbonate. Each film-coated tablet contains 800 mg of sevelamer carbonate<br />- The other ingredients are microcrystalline cellulose, sodium chloride and zinc stearate. The tablet coating contains hypromellose (E464) and diacetylated monoglycerides. The printing ink contains iron oxide black (E172), isopropyl alcohol and propylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Renvela film-coated tablets are white tablets with Renvela 800 imprinted on one side. The tablets are packed in high density polyethylene bottles with a polypropylene cap and an induction seal.
Pack sizes:
Each bottle contains 30 tablets or 180 tablets.
Packs of 1 bottle of 30 or 180 tablets (no outer carton) and a multipack containing 180 (6 bottles of 30) tablets
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Genzyme Europe B.V.<br />Paasheuvelweg 25 1105 BP Amsterdam<br />The Netherlands</p><p><strong>Manufacturer</strong><br />Genzyme Ireland Limited<br />IDA Industrial Park<br />Old Kilmeaden Road<br />Waterford<br />Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>فوسفور المصل في الدم.<br />یُستعمل ھذا الدواء للتحكّم بفرط فوسفاتاز الدم (مستویات مرتفعة من الفوسفات في الدم) لدى :<br />&bull; المرضى البالغین الذین یخضعون لغسیل الكلى (تقنیّة تصفیة الدم). یمكن استعمالھ لدى المرضى الذین یخضعون للغسیل الدموي<br />(عبر استعمال آلة تنقیة للدم) أو غسیل الكلى البریتوني (عندما یتمّ ضخّ سائل في داخل البطن ویقوم غشاء داخليّ في الجسم بتصفیة<br />الدم)؛<br />&bull; المرضى المصابین بمرض كلويّ مزمن (طویل الأمد) ولكن لا یخضعون لغسیل الكلى ویكون مستوى فوسفور المصل (الدم) لدیھم<br />مساویاً ل ۱٫۷۸ ملمول/ل أو أعلى.<br />یجب استعمال ھذا الدوا ء مع علاجات أخرى مثل مكمّلات الكلسیوم والفیتامین دي لمنع الإصابة بمرض في العظم.<br />یمكن أن تؤدّي زیادة مستویات فوسفور المصل إلى تشكّل ترسّبات صلبة في جسمك تسُمّى تكلّسًا. یمكن أن تؤدّي ھذه الترسّبات إلى<br />تصلّب أوعیتك الدمویّة مما یصعّب عملیّة ضخّ الدم في جمیع أنحاء الجسم. ویمكن أن تؤدّي أیضً ا زیادة فوسفور المصل إلى حكّة جلدیّة<br />واحمرار العینین وألم العظم وكسور العظم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong><u>موانع الاستعما ل:</u><br />لا تأخذ رینفیلا :</strong><br />&bull; إذا كنت تعاني من حساسیّة ضد المادة الفاعلة أو ضدّ أيّ مكوّن آخر من مكوّنات ھذا الدواء (المذكورة في القسم ٦).<br />&bull; إذا كانت مستویات الفوسفات في دمك منخفضة (سوف یتحقق طبیبك منھا )<br />&bull; إذا كنت تعاني من انسداد في الأمعاء<br /><strong>تحذیرات واحتیاطا ت</strong><br />تحدّث إلى طبیبك قبل أخذ رینفیلا إذا كانت إحدى الحالات أدناه تنطبق علیك:</p><p>&bull; مشاكل في البلع. یمكن أن یصف طبیبك رینفیلا، مسحوق لتحضیر مستعلق فمو ي<br />&bull; مشاكل في الحركیّة (الحركة) في معدتك وأمعائك<br />&bull; المرض في كثیر من الأحیان<br />&bull; التھاب فاعل في الأمعاء<br />&bull; الخضوع لجراحة كبیرة في المعدة أو الأمعاء<br />تحدثّ إلى طبیبك وأنت تأخذ رینفیلا:<br />&bull; إذا أصبت بألم حاد في البطن أو باضطرابات في المعدة أو الأمعاء أو بدم في البراز (نزیف معدي معوي). یمكن أن یكون<br />سبب ھذه العوارض مرض التھاب أمعاء خطیر ناتج عن رواسب بلوّرات سیفیلامیر في أمعائك. اتصل بطبیبك الذي سیقرّر<br />مواصلة العلاج أو لا.<br />العلاجات الإضافیةّ<br />إمّا بسبب حالة كلیتیك أو علاج غسیل الكلى الذي تخضع لھ یمكن أن:<br />&bull; تنخفض أو ترتفع مستویات الكلسیوم في دمك. بما أنّ ھذا الدواء لا یحتوي على الكلسیوم، قد یصف لك طبیبك أقراصًا إضافیّة<br />من الكلسیوم.<br />&bull; تكون كمیّة الفیتامین دي في دمك منخفضة. لذلك، یمكن أن یراقب طبیبك مستویات الفیتامین دي في دمك فیصف كمیّة إضافیّة<br />من الفیتامین دي عند الضرورة. وإذا لم تأخذ مكمّلات من الفیتامینات المتعددة قد تنخفض أیضًا لدیك مستویات الفیتامین أ وإي<br />وكاي وحمض الفولیك في دمك وبالتالي قد یراقب طبیبك ھذه المستویات ویصف فیتامیات إضافیّة عند الضرورة.<br />&bull; یكون مستوى البیكربونات في دمك مضطربًا ویكون لدیك حموضة مرتفعة في الدم وفي أنسج ة أخرى في جسمك. یجب أن<br />یراقب طبیبك مستوى البیكربونات في دمك.<br />ملاحظة خاصة للمرضى الذین یخضعون لغسیل الكلى البریتوني<br />قد تصُاب بالتھاب الصفاق (عدوى في السائل البطني) بسبب غسیل الكلى البریتوني الذي تخضع لھ. یمكن الحد من ھذا الخطر عبر<br />الالتزام الدقیق بتقنیّات التعقیم خلال تغییر الأكیاس. یجب أن تعُلم طبیبك على الفور إذا أصبت بأيّ إشارات أو عوارض جدیدة مثل<br />التلبكّ المعوي أو انتفاخ البطن أو ألم البطن أو إیلام البطن عند اللمس أو تصلبّ البطن أو الإمساك أو الحمى أو القشعریرات أو الغثیان<br />أو التقیّؤ.<br /><u><strong>الأطفال</strong></u><br />لم تتمّ دراسة السلامة والفعالیّة لدى الأطفال (دون عمر الستّ سنوات). لذلك لا یوصى باستعمال ھذا الدواء لدى الأطفال دون عمر<br />الستّ سنوا ت.<br /><strong>أدویة أخرى ورینفی لا</strong><br />أعلم طبیبك إذا كنت تأخذ حالیًا أو أخذت مؤخّرًا أو قد تأخذ أيّ أدویة أخرى.<br />&bull; لا ینبغي أخذ رینفیلا في الوقت ذاتھ مع السیبروفلوكساسین (مضاد حیوي).<br />&bull; إذا كنت تأخذ أدویة لعلاج مشاكل النظم القلبي أو للصرع، یجب أن تستشیر طبیبك عند أخذ رینفیلا.<br />&bull; إنّ تأثیرات أدویة مثل سیكلوسبورین ومیكوفینولات موفیتیل وتاكرولیموس (أدویة تسُتعمل لكبح جھاز المناعة) قد تخفّ بسبب<br />رینفیلا. سوف یعلمك طبیبك إذا كنت تأخذ ھذه الأدویة.<br />&bull; یمكن أن یحصل بصورة غیر شائعة نقص في ھرمون الغدّة الدرقیّة لدى بعض الأشخاص الذین یأخذون اللیفوثیروكسین<br />(المستعمل لعلاج المستویات المنخفضة لھرمون الغدّة الدرقیّة) ورینفیلا. لذلك قد یراقب طبیبك مستویات ھرمون تحفیز الغدة<br />الدرقیةّ في دمك بدقّة أكبر.</p><p>&bull; إنّ الأدویة التي تعالج حرقة المعدة وارتجاع المعدة أو المريء، مثل أومیبرازول أو بانتوبرازول أو لانسوبرازول المعروفة<br />ب &quot;مثبطات مضخة البروتون&quot;، یمكن أن تحدّ من فعالیّة رینفیلا. یمكن أن یراقب طبیبك مستوى الفوسفات في دمك.<br />سوف یتحقق طبیبك من أيّ تفاعلات بین رینفیلا وأدویة أخرى بشكل منتظم.<br />في بعض الحالات التي ینبغي فیھا أخذ رینفیلا في الوقت ذاتھ مع دواء آخر، قد ینصحك طبیبك بأ خذ ھذا الدواء قبل ساعة من أخذ رینفیلا<br />أو بعد ۳ ساعات من أخذه، أو قد یفكّر أیضا في فحص مستویات ذلك الدواء في الدم.<br /><strong>الحمل والإرضا ع</strong><br />إذا كنت حاملاً أو مرضعة، أو كنتِ تعتقدین نفسك حاملاً أو كنتِ تخططین للحمل، استشیري طبیبك قبل أخذ ھذا الدواء.<br />إنّ الخطر المحتمل لرینفیلا في خلال فترة الحمل لدى البشر غیر معروف. تحدّثي إلى طبیبك الذي سیقرّر إذا كنت تستطیعین مواصلة<br />العلاج برینفیلا.<br />من غیر المعروف إذا كان رینفیلا یُفرز في حلیب الثدي وإذا كان یؤثرّ على طفلك. تحدّثي إلى طبیبك الذي سیقرّر إذا كان یمكنك إرضاع<br />طفلك أو لا وإذا كان من الضروريّ إیقاف العلاج برینفیلا.<br /><strong>قیادة السیّارات واستعمال الآلا ت</strong><br />من غیر المحتمل أن یؤثرّ رینفیلا على قدرتك على قیادة السیّارة أو على استعمال آلات.<br /><strong>السواغا ت</strong><br />یحتوي ھذا الدواء على أقلّ من ۱ ملمول من الصودیوم ( ۲۳ ملغ) في القرص، أيّ أنھّ &quot;خالِ من الصودیوم&quot; بشكل أساسيّ .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب علیك أن تأخذ رینفیلا وفقًا لوصفة طبیبك. سوف یحدّد الطبیب الجرعة وفقًا لمستوى فوسفور الدم لدیك.<br />تبلغ الجرعة الموصى بھا من أقراص رینفیلا للبالغین والمسنّین قرصًا إلى قرصین من ۸۰۰ ملغ مع كلّ وجبة طعام، ۳ مرّات في الیوم.<br />تحقق مع الطبیب أو الصیدليّ أو الممرّضة إذا لم تكن متأكّدًا.<br />خذ رینفیلا بعد وجبتك أو مع الطعام.<br />یجب بلع الأقراص كاملة. لا تسحقھا أو تمضغھا أو تكسرھا.<br />مبدئیاً سوف یتحقق طبیبك من مستویات الفوسفور في دمك كلّ ۲- ٤ أسابیع وقد یعدلّ جرعة رینفیلا عند الضرورة لبلوغ مستوى مناسب<br />من الفوسفات.<br />تقیدّ بالنظام الغذائي الذي وصفھ طبیبك.<br /><strong>إذا أخذت رینفیلا أكثر مما یجب علی ك</strong><br />في حالة فرط جرعة محتمل یجب علیك الاتصال بطبیبك على الفور.<br /><strong>إذا نسیت أخذ رینفی لا</strong><br />إذا فوّت جرعة واحدة، یجب عدم أخذ ھذه الجرعة ویجب أخذ الجرعة التالیة في موعدھا الاعتیادي مع الطعام. لا تأخذ جرعة مضاعفة<br />للتعویض عن الجرعة التي نسیت أخذھا.<br /><strong>إذا توقفت عن أخذ رینفی لا</strong><br />إنّ أخذ علاج رینفیلا مھمّ للحفاظ على مستوى مناسب من الفوسفات في دمك. إنّ التوقّف عن أخذ رینفیلا یؤّدي إلى نتائج مھمّة مثل<br />التكلّس في الأوعیة الدمویّة. إذا فكّرت في إیقاف علاج رینفیلا الذي تأخذه، اتصل بطبیبك أو بالصیدليّ أوّلاً.<br />إذا كان لدیك أسئلة أخرى حول استعمال ھذا الدواء، اطرحھا على الطبیب أو الصیدليّ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدویة كلھّا، یمكن أن یسببّ ھذا الدواء تأثیرات جانبیةّ لا تصیب المرضى كلھّم.<br />الإمساك تأثیر جانبيّ شائع جدًا (قد یصُیب أكثر من شخص من أصل ۱۰ أشخاص). یمكن أن یكون عارضًا مبكرًا لانسداد الأمعاء. في<br />حالة الإمساك، الرجاء أعلم الطبیب أو الصیدليّ.<br />یمكن أن یكون بعض التأثیرات الجانبیّة خطیرًا. إذا أصبت بأيّ من التأثیرات الجانبیّة التالیة، اطلب مساعدة طبیّة فوریّة :<br />- ارتكاس تحسسي (تتضمّن العوارض الطفح والشرى والتورّم وصعوبة التنفسّ). ھذا تأثیر جانبيّ نادر جدًا (قد یصُیب لغایة شخص<br />من أصل ۱۰۰۰۰ شخص).<br />- أفید عن انسداد الأمعاء (تتضمّن العوارض: الانتفاخ الشدید وألم البطن والتورّم أو التشنجّات والامساك الشدید). عدد مرّات الحصول<br />غیر معروف (لا یمكن تقدیر عدد مرّات الحصول من البیانات المتوافرة).<br />- أفید عن تمزّق في جدار الأمعاء (تتضمّن العوارض: ألم المعدة الحاد والقشعریرات والحمى والغثیان والتقیؤّ أو ألم البطن عند<br />اللمس). عدد مرّات الحصول غیر معروف.<br />- أفید عن التھاب خطیر للأمعاء الغلیظة (تتضمّن العوارض: ألم البطن الشدید، اضطرابات معدیةّ أو معویةّ، أو دم في البراز (نزیف معدي<br />معوي) ورواسب بلوّرات في الأمعاء. عدد مرّات الحصول غیر معروف .<br />أفید عن تأثیرات جانبیةّ أخرى لدى المرضى الذین یأخذون رینفیلا:<br /><u>الشائعة جدًا:</u><br />تقیؤّ، ألم في أعلى البطن، غثیان<br />الشائعة (قد تصیب لغایة شخص من أصل ۱۰ أشخاص):<br />إسھال، ألم في المعدة، عسر ھضم، نفخة<br /><u>التأثیرات غیر المعروفة معدلّ الحصول:</u><br />حالات حكّة وطفح وبطء حركة الأمعاء<br />الإبلاغ عن التأثیرات الجانبیةّ<br /><strong>للإبلاغ عن الأعرا ض الجانبیة<br />&bull; المملك ة العربیة السعودی ة</strong><br />المرك ز الوطني للتیقظ:<br />مركز الاتصال بھیئة الغذاء والدوا ء : ۱۹۹۹۹<br />الإلكترون ي البری د : npc.drug@sfda.gov.sa<br />الإلكترون ي الموق ع : / https://ade.sfda.gov.sa<br />سانوفي-التیقظ الدوائي : KSA_Pharmacovigilance@sanofi.co</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ ھذا الدواء بعیدًا عن نظر الأطفال ومتناولھم.<br />لا تستعمل ھذا الدواء بعد انقضاء تاریخ الصلاحیةّ المدوّن على الزجاجة وعلبة الكرتون بعد الأحرف &rdquo; &ldquo;EXP . یشیر تاریخ انتھاء<br />الصلاحیةّ إلى الیوم الأخیر من الشھر المذكور .<br />یجب إبقاء الزجاجة مغلقة بإحكام لحمایتھا من الرطوبة.<br />لا یحُفظ في درجة حرارة تتجاوز ۳۰ درجة مئویّة.<br />لا ترمِ أيّ أدویة في میاه الصرف الصحّي أو مع النفایات المنزلیّة. إسأل الصیدليّ عن كیفیّة التخلّص من الأدویة التي لم تعد تستعملھا،<br />فمن شأن ھذه الإجراءات المساعدة على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفاعلة ھي سیفیلامیر كربونات. یحتوي كلّ قرص مغلّف على ۸۰۰ ملغ من سیفیلامیر كربونات.<br />- المكوّنات الأخرى ھي سلولوز دقیق البلوریةّ وكلورید الصودیوم وستیارات الزنك. یح توي غلاف القرص على ھیبرومیلوز (إي<br />٤٦٤ ) وأحادي الغلیسیرید الثنائي الأسیتیل. یحتوي حبر الطبع على أكسید الحدید الأسود (إي ۱۷۲ ) وكحول الإیزوبروبیل<br />وبروبیلین الغلیكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">كیف ھو شكل رینفیلا ومحتویات العلب ة<br />أقراص رینفیلا المغلفّة ھي أقراص بیضاء مطبوع علیھا Renvela 800 على جھة واحدة. الأقراص موضّبة في زجاجات إیثیلین<br />متعدد عالي الكثافة مع غطاء من مادة البولي بروبیلین وختم تعریفي.<br />أحجام العلب:<br />تحتوي كلّ زجاجة على ۳۰ قرصًا أو ۱۸۰ قرصًا.<br />علب من زجاجة واحدة من ۳۰ أو ۱۸۰ قرصًا (ما من علبة كرتونیّة خارجیّة) وعلبة متعددة تحتوي على ۱۸۰ ( ٦ زجاجات من ۳۰ )<br />قرصًا.<br />قد لا تكون أحجام العلب كلّھا مسوّقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسوی ق</strong><br />Genzyme Europe B.V.<br />Paasheuvelweg 25<br />1105 BP Amsterdam<br />The Netherlands</p><p><strong>المصنعّ</strong><br />Genzyme Ireland Limited<br />IDA Industrial Park<br />Old Kilmeaden Road<br />Waterford<br />Ireland</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ینایر/۲۰۲۰
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Renvela 800 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 800 mg sevelamer carbonate. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
The white to off-white tablets are imprinted with “RENVELA 800” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.<br />Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus &ge; 1.78 mmol/l.<br />Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology<br />Starting dose</u><br />The recommended starting dose of sevelamer carbonate is 2.4 g or 4.8 g per day based on clinical needs and serum phosphorus level. Renvela must be taken three times per day with meals.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Serum phosphorus level in patients</td><td>Total daily dose of sevelamer carbonate to be<br />taken over 3 meals per day</td></tr><tr><td>1.78 &ndash; 2.42 mmol/l (5.5 &ndash; 7.5 mg/dl)</td><td>2.4 g*</td></tr><tr><td>&gt; 2.42 mmol/l (&gt; 7.5 mg/dl)</td><td>4.8 g*</td></tr></tbody></table><p>*Plus subsequent titrating, see section &ldquo;Titration and maintenance&rdquo;</p><p>For patients previously on phosphate binders (sevelamer hydrochloride or calcium based), Renvela should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.<br /><u>Titration and maintenance</u><br />Serum phosphorus levels must be monitored and the dose of sevelamer carbonate titrated by 0.8 g three times per day (2.4 g/day) increments every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter.<br />Patients taking sevelamer carbonate should adhere to their prescribed diets.</p><p>In clinical practice, treatment will be continuous based on the need to control serum phosphorus levels and the daily dose is expected to be an average of approximately 6 g per day.<br /><u>Special populations</u><br />Elderly population<br />No dosage adjustment is necessary in the elderly population.<br />Hepatic impairment<br />No studies have been performed in patients with hepatic impairment.<br />Paediatric population<br />The safety and efficacy of Renvela in children below the age of 6 years or in children with a BSA below<br />0.75 m2 have not been established. Not data are available.<br />The safety and efficacy of Renvela in children over 6 year of age and a BSA &gt;0.75 m2 have been established. Current available data are described in section 5.1.<br />For paediatric patients the oral suspension should be administered, as tablet formulations are not appropriate for this population.<br /><u>Method of administration Oral use.</u><br />Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration. Renvela should be taken with food and not on an empty stomach.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Hypophosphataemia
• Bowel obstruction.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of sevelamer carbonate have not been established in adult patients with chronic kidney disease not on dialysis with serum phosphorus &lt; 1.78 mmol/l. Therefore it is currently not recommended for use in these patients.<br />The safety and efficacy of sevelamer carbonate have not been established in patients with the following disorders:<br />&bull; dysphagia<br />&bull; swallowing disorders<br />&bull; severe gastrointestinal motility disorders including untreated or severe gastroparesis, retention of gastric contents and abnormal or irregular bowel motion<br />&bull; active inflammatory bowel disease<br />&bull; major gastrointestinal tract surgery<br />Treatment of these patients with Renvela should only be initiated after careful benefit/risk assessment. If the therapy is initiated, patients suffering from these disorders should be monitored. Renvela treatment should be reevaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.<br /><u>Intestinal obstruction and ileus/subileus</u><br />In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with sevelamer hydrochloride (capsules/tablets), which contains the same active moiety as sevelamer carbonate. Constipation may be a preceding symptom. Patients who are constipated should be monitored carefully while being treated with Renvela. The treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.</p><p><u>Fat-soluble vitamins and folate deficiency</u><br />Patients with CKD may develop low levels of fat-soluble vitamins A, D, E and K, depending on dietary intake and the severity of their disease. It cannot be excluded that sevelamer carbonate can bind fat-soluble vitamins contained in ingested food. In patients not taking supplemental vitamins but on sevelamer, serum vitamin A, D, E and K status should be assessed regularly. It is recommended that vitamin supplements be given if necessary. It is recommended that CKD patients not on dialysis are given vitamin D supplements (approximately 400 IU of native vitamin D daily) which can be part of a multivitamin preparation to be taken apart from their dose of sevelamer carbonate. In patients undergoing peritoneal dialysis additional monitoring of fat-soluble vitamins and folic acid is recommended, since vitamin A, D, E and K levels were not measured in a clinical study in these patients.<br />There is at present insufficient data to exclude the possibility of folate deficiency during long term sevelamer carbonate treatment. In patients not taking supplemental folic acid but on sevelamer, folate level should be assessed regularly.<br /><u>Hypocalcaemia/hypercalcaemia</u><br />Patients with CKD may develop hypocalcaemia or hypercalcaemia. Sevelamer carbonate does not contain any calcium. Serum calcium levels should therefore be monitored at regular intervals and elemental calcium should be given as a supplement if required.<br />Metabolic acidosis<br />Patients with CKD are predisposed to developing metabolic acidosis. As part of good clinical practice, monitoring of serum bicarbonate levels is therefore recommended.<br /><u>Peritonitis</u><br />Patients receiving dialysis are subject to certain risks for infection specific to dialysis modality. Peritonitis is a known complication in patients receiving peritoneal dialysis and in a clinical trial with sevelamer hydrochloride, a greater number of peritonitis cases were reported in the sevelamer group than in the control group. Patients on peritoneal dialysis should be closely monitored to ensure the correct use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.<br /><u>Swallowing and choking difficulties</u><br />Uncommon reports of difficulty swallowing the Renvela tablet have been reported. Many of these cases involved patients with co-morbid conditions including swallowing disorders or oesophageal abnormalities. Proper swallowing ability should be carefully monitored in patients with co-morbid conditions. The use of sevelamer carbonate powder in patients with a history of difficulty swallowing should be considered.<br /><u>Hypothyroidism</u><br />Closer monitoring of patients with hypothyroidism co-administered with sevelamer carbonate and levothyroxine is recommended (see section 4.5).<br /><u>Hyperparathyroidism</u><br />Sevelamer carbonate is not indicated for the control of hyperparathyroidism. In patients with secondary hyperparathyroidism sevelamer carbonate should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.<br /><u>Inflammatory gastrointestinal disorders</u><br />Cases of serious inflammatory disorders of different parts of the gastrointestinal tract (including serious complications such as haemorrhage, perforation, ulceration, necrosis, colitis and colonic/caecal mass) associated with the presence of sevelamer crystals have been reported (see section 4.8). Inflammatory disorders may resolve upon sevelamer discontinuation. Sevelamer carbonate treatment should be re- evaluated in patients who develop severe gastrointestinal symptoms.</p><p><u>Excipients</u><br />This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dialysis</u><br />Interaction studies have not been conducted in patients on dialysis.<br /><u>Ciprofloxacin</u><br />In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, decreased the bioavailability of ciprofloxacin by approximately 50% when co- administered with sevelamer hydrochloride in a single dose study. Consequently, sevelamer carbonate should not be taken simultaneously with ciprofloxacin.<br /><u>Ciclosporin, mycophenolate mofetil and tacrolimus in transplant patients</u><br />Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when co-administered with sevelamer hydrochloride without any clinical consequences (e.g., graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of ciclosporin, mycophenolate mofetil and tacrolimus should be considered during the use of combination and after its withdrawal.<br /><u>Levothyroxine</u><br />Very rare cases of hypothyroidism have been reported in patients co-administered with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, and levothyroxine. Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving sevelamer carbonate and levothyroxine.<br /><u>Anti-arrhythmics and anti-seizure medicinal products</u><br />Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials. Therefore, possible reduction in absorption cannot be excluded. The anti-arrhythmic medical product should be taken at least one hour before or three hours after Renvela, and blood monitoring can be considered.<br /><u>Proton pump inhibitors</u><br />During post-marketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate. Caution should be exercised when prescribing PPI to patients concomitantly treated with Renvela. The phosphate serum level should be monitored and the Renvela dosage adjusted consequently.<br /><u>Bioavailability</u><br />Sevelamer carbonate is not absorbed and may affect the bioavailability of other medicinal products. When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer carbonate, or the physician should consider monitoring blood levels.<br /><u>Digoxin, warfarin, enalapril or metoprolol</u><br />In interaction studies in healthy volunteers, sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-indent:50px"><u>Pregnancy</u><br />There are no or limited amount of data from the use of sevelamer in pregnant women. Animal studies have shown some reproductive toxicity when sevelamer was administered to rats at high doses (see section 5.3). Sevelamer has also been shown to reduce the absorption of several vitamins including folic acid (see sections 4.4 and 5.3). The potential risk to humans is unknown. Sevelamer carbonate should only be given to&nbsp;&nbsp;pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus.<br /><u>Breast-feeding</u><br />It is unknown whether sevelamer/metabolites are excreted in human milk. The non-absorbed nature of sevelamer indicates that excretion of sevelamer in breast milk is unlikely. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with sevelamer carbonate should be made taking into account the benefit of breast-feeding to the child and the benefit of sevelamer carbonate therapy to the woman.<br /><u>Fertility</u><br />There are no data from the effect of sevelamer on fertility in humans. Studies in animals have shown that sevelamer did not impair fertility in male or female rats at exposures at a human equivalent dose 2 times the maximum clinical trial dose of 13 g/day, based on a comparison of relative BSA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevelamer has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />The most frequently occurring (&ge; 5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class. Most of these adverse reactions were mild to moderate in intensity.<br /><u>Tabulated list of adverse reactions</u><br />The safety of sevelamer (as either carbonate and hydrochloride salts) has been investigated in numerous clinical trials involving a total of 969 haemodialysis patients with treatment duration of 4 to 50 weeks<br />(724 patients treated with sevelamer hydrochloride and 245 with sevelamer carbonate), 97 peritoneal dialysis patients with treatment duration of 12 weeks (all treated with sevelamer hydrochloride) and 128 patients with CKD not on dialysis with treatment duration of 8 to 12 weeks (79 patients treatment with sevelamer hydrochloride and 49 with sevelamer carbonate).<br />Adverse reactions that occurred during clinical trials or that were spontaneously reported from post- marketing experience are listed by frequency in the table below. The reporting rate is classified as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to<br />&lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RESRXhpZgAATU0AKgAAAAgABAE7AAIAAAAYAAAISodpAAQAAAABAAAIYpydAAEAAAAwAAAQ2uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE11aGFtbWVkLCBVc21hbiAvU0EvRVhUAAAFkAMAAgAAABQAABCwkAQAAgAAABQAABDEkpEAAgAAAAM2MAAAkpIAAgAAAAM2MAAA6hwABwAACAwAAAikAAAAABzqAAAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAMjAyMTowODoxMCAxNToxNzoyOAAyMDIxOjA4OjEwIDE1OjE3OjI4AAAATQB1AGgAYQBtAG0AZQBkACwAIABVAHMAbQBhAG4AIAAvAFMAQQAvAEUAWABUAAAA/+ELKmh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDgtMTBUMTU6MTc6MjguNTk5PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk11aGFtbWVkLCBVc21hbiAvU0EvRVhUPC9yZGY6bGk+PC9yZGY6U2VxPg0KCQkJPC9kYzpjcmVhdG9yPjwvcmRmOkRlc2NyaXB0aW9uPjwvcmRmOlJERj48L3g6eG1wbWV0YT4NCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgPD94cGFja2V0IGVuZD0ndyc/Pv/bAEMABwUFBgUEBwYFBggHBwgKEQsKCQkKFQ8QDBEYFRoZGBUYFxseJyEbHSUdFxgiLiIlKCkrLCsaIC8zLyoyJyorKv/bAEMBBwgICgkKFAsLFCocGBwqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKv/AABEIAdwC8QMBIgACEQEDEQH/xAAfAAABBQEBAQEBAQAAAAAAAAAAAQIDBAUGBwgJCgv/xAC1EAACAQMDAgQDBQUEBAAAAX0BAgMABBEFEiExQQYTUWEHInEUMoGRoQgjQrHBFVLR8CQzYnKCCQoWFxgZGiUmJygpKjQ1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4eLj5OXm5+jp6vHy8/T19vf4+fr/xAAfAQADAQEBAQEBAQEBAAAAAAAAAQIDBAUGBwgJCgv/xAC1EQACAQIEBAMEBwUEBAABAncAAQIDEQQFITEGEkFRB2FxEyIygQgUQpGhscEJIzNS8BVictEKFiQ04SXxFxgZGiYnKCkqNTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqCg4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2dri4+Tl5ufo6ery8/T19vf4+fr/2gAMAwEAAhEDEQA/APpGiisTW/EjaRqtlptto2oatd3kM06x2TQLsSJo1YsZZEHWZMAEnr6UAbdFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVVa/8cXumWyT33gnxBFE80UCt5tg2XlkWNBxc93dRnoM5OBQB1tFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlUAdJRXN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAHSUVzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVQB0lFclpvji91fSrTUtP8ABPiCa0vIUngk82wXejqGU4NyCMgjgjNWf+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqgDpKK5Kw8cXup2zz2PgnxBLEk0sDN5tguHikaNxzc9nRhnocZGRVn/hKNX/6ETxB/wB/9P8A/kqgDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6SiuSj8cXsuqz6angnxAbu3hjnlj82w+VJGdUOftODkxPwDkbeeozZ/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm4fF0/9r6dYal4Y1jTP7RmaCCe5e0ePesTy4PlTuwysTc4xmukoAKKKKACubvv+Sp6F/wBgXUv/AEfY10lc3ff8lT0L/sC6l/6PsaAJfHDajH4M1GfRNSl02+ghaWGeOON/mA4DB1YFSevGfQisfw742uJvAE95rManXNMkawvLdcL5l2CEUAdhIShHs4rd8W2eqaj4XvLLQ4rSS7uEMY+2TtFGoPVsqjE49Mc+orBHge7bxsPFJaCKSS1WS50pLhjBLeoCschfYCQFZhnbn7p25AoVtU/6/rX52D+v6/ra5Q8A+KdWHg9tR8VX9zrGqXOpXFlBZ28MKZeJ3XZEAE7ISTI3GOorcg+IWmXdlG1paX02oSXUlmNKVEFys0Yy6HLhBtHO4vt5HJyM8na/DXW5/DENnrdloFzc2Orz6lb280r3FtciZpC0coeEFcCThgG5AOO1a58D32n3mk6z4Y0vQNJv7F5fN0y3zFayxyqquPNSIHflFIby+2Md6rR7/wBbf1/Wp6ef6/8AA/rbkrTW/Ej+FLu9tvE2r2s0fi3+zm+0RW8khheWKPaQ8bKpUE42YXOeDXXa7qWv+Ar3S7y71qXXNFvL2Ozu1vYIUntzIdqSI0SIpUNjIKk89ax5/AfjRNPvLaBtBuFu/EK6yVe4mhMQWVZPL3CN927aBnC7efvZ46G/8NeIPFup6a3in+z9P0zTrpbsWOn3D3DXMqcpvkeOPCg87Qpzgc0Rtyxv5X9LRv8AqKW8vnb73b9DktS8Talp+teK7CT4g3UWoabKn9lac1tZySXW6FZNnlLCJJBuJX5SDjvnmvR7TW7m18Cw614ktvsd3HYrcXluv8Em3LIOeueAPwrlV8C6zq+peJf+Egh061t9VuI7uzurG+kkns5oo1SNgGhUZ+Xdnd7YIOalvdG8da9Y6dpfiK30RrOO4R9QnsdVuYJblV5BQLCDGdwVsB+duMgHNStY266f8H/g/Ip25r9Nf6/yLnw+8Q6zf3Gs6N4taP8AtjTrhZcRqFBt5l3x4wBnb8yZ/wBjmnfEbxHeeHLLTZ45rmx0yW5Kalqdrbid7KLYSG2lWABbALFWAHas9/A2raJ8R7HX/CYhltDaNa6iNW1m6mlmQsCuzesmNmCR82DuIwOtdbrNtq8lxbT6PJalYVkE1rdMypcAgYXcoO3nndtbHTBzw3qk1/Vv8xLRtf1qc2fGT6B4VvfENzcTeKdGiKGC70tIC4i2/M8nzqpIbOSoGMj5Rg1q6h42tdMkH2rTb4R/Y47tpkMLIm9tiRHEmd5bgYG3/awCapeFfBC6U2vTX9pY2ceuMpl0uwYvbRAKVYglUyz5yx2r247mh4M8O3beAri11EWmrfaJPskYvFJjmson2RhupJKBmz6tmh9fkC6f1/XVfcWfFvjjU9G0nTprPw7qKz3Wp21m8UpgDIHZSQD5m1iQSoIbAOckYq/qHj7T9LmH2yyv0tY547W6vQiGG0mfbtRzv3E5dQSgZQTyRXNr8PNdj8PJbQT2kRt9bt9Ss9Oe8mngtYoiMxLMyb8HBYDZhc4AxzVpfhyI/Et9d3OgeGdXi1Cf7U17fW4+02shUZCgxt5i7hkAupGe9NW69/0X/B+f4p36f1v/AMAvH4paOILu5Gnav9kstRGnXVw1psWGQ7QCVYhypLgfKpPqACCdrRfFFvrOr6jpZsryxvdP2NLDdKmWjfOyRSjMMHaeCQRjkCuCvfAnjK78O+ItOFvoSvq+tJqUbf2jNiNAyMUP+j8n90oz/tH056nRdD161+JGsa7fwacljqNnbwKILuSSVGi3dVMSjB3nvxtHrwo2sr9v0X63G9G/66/5HX1zfjz/AJF21/7DWlf+nC3rpK5vx5/yLtr/ANhrSv8A04W9IDoZ42lt5I45ngd1KrLGFLISPvDcCMj3BHtXD+E9S1Kxu/FOm+LPEVxeXOmSebHLLDBHstGQskqhIxk/eBzkZTgDv3dcX4u8D3Wv+KdJ1TT71LSJFNtqsbAn7Xa7g4j6YzvXHOOHbnsTrbvp6ef9dB9PTX+v63DR9X1LQtAs11u41PxHrF+jXMdpHDbxypGMZGAI0AUMuSxyScDsKh/4W1oc72sel6frOqTXVnJeQxWliSWWM7XQFioLg8FQeCMdSAZ/Gngr+39Z03V4tM0jV5LKKSBrDWEBhkRyp3BtjlHBQYO05BI96rWXg/VNP8e6NqVhpuiWOj2FlcWzW9nK0RQzOrnZGIgpAKAZyN24njpVKzevn+tv0Fsv6+ZcsfiJBfaVq14PD+sQy6TcpazWUwt1neRtuAo84j+NTyRnPGa3dX1620XT4bm8imMlxIsMFrGoaWWVukajOM9ec4ABJOBmuavNBlf4uW9zaTKLK4s1uNSgxndJC2IG9iS7fXyh6VreMfD95rlrp8+kzww6jpd6l7bC4B8qRgGUo5HIBViMgEjg4PSp0sn/AF2f6sOrX9d0ivF8QNPltf8Ajw1FNR+2NYjSnjQXDTqm8oDv8vGz5t2/bjvVWX4o6JBbRNcWmqR3Lagmmy2f2QtLbztjAfaSoBBBBDEMPu5qXVtC13VrjRtbaPT4NW0iaSWKzFzI8EivGUZTL5YYHBBDeXxjGDmsDWPAfiK7lOo2UelHUbzWbbVLyOW8lSKIW6qqRIwhJfODlyq9elNW5lfy/Nfpf+tzpp5/r/wP6227r4mafZ2upz3Wj6vGNInEWoqYos2qkAiQnzMMpBB+Qs2P4amv/iLp1nqmq6fDpmrXtxpNql3ciC1CqYmz8ys7KGwATx1wQMkEDmtY8D+LNTtfHUKQ6Mn/AAkvlC3Jv5f3QRBHl/3HXAzgd+Pepx4X8aS6xr2oTWWgxtqmjx6dHGmqTNsZN43E/ZxwfMPGOw9ciX8N1vb8bf5j0vb+t1+lzo7Xx/pVxqMFtLDd2sN1Ytf2t5cIqxXEKBS7DDFlwGH3lXPbNMtfiDp099a29zp+pWK38LT6fNcQKVvVVdxEYRmYNt52MqsewNcq3w78RX0Ph2x1KPS0srDQ59IvHgv5DIRKioXjBhAOAgOCRyxHbJ3Lfwtrs8mh/wBrpppHhtWayNvcyZvJPKMSmQGP90uCSQDJyevHNySTdv61f6W/raVeyv8A1ov1v6FjSPiXpWstpLQWGpwW2rTy21tdXMCxoZY92UILbwSEYg7cdiQeK7GvKdM8C+L7LSfC1nLDohOi6vLfzuuoTfvEcyfKo8jr+9br/dHrx6tQ7dA6/wBd3/wAoooqRhRRRQBzfw4/5JZ4U/7Atn/6ISsnTNW1bxxruuR6bq02i6Vo96bFJLOKJ5rmZVzISZUdVUFgAAuTjOe1a3w4/wCSWeFP+wLZ/wDohKzbTwxrnhXX9WvPCg069sNXuftc1jfTvbGCYjDskiRyZDYB2lRg55oW+v8AT0/S4+mn9L+rF/8Atq/8OxvD4gdtTu7q9MOmQ2UKJJcqIg23BYKCNrkszKOOwIFU5/iholppbXd1a6nFLFfpp9xZ/ZC81vM5G0OFJUA5BDBiDn5STxU+teHNX1C80jWop7WTVdJuJJoraRmjt3V4yhj3hSw4Od+085+UA4HP654C8QX9he3Nkml/2rqmrWmoXUct3IsMK2+zbGjCIlydnLFV+9nHGKa3V/L81+l/63T20/rf/gf1ttXfxJsrKLVmuNF1hX0Yhr6LyosxQldwmz5m1lIBOAS/B+Xg067+JOmQX2p2lrpurX0umWkd7P5FqFUwuCdymRlDYAJ464IGSCBhax4N8WanceNnS30ZF8RWEVpb51CXMRRWTc37j0cnjuAO+Q228JeNEvtZuprPQVbUNEh0yNE1OZgrRhxvJ+zjg+YTjtgDnOQn8N12/T/P8x6XX9dv+D9x1Nh4702+1a2svs95bpe2bX1ndToqxXMShSxXDFlxuH31XPbNQW/xG0ua4shNY6lbWupIX068lgUx3uF3YQIzOGKgkK6qW7A1ztr4E8SNP4Xiv4tKW00vRZtKvGhv5TIwkVULxgwgcCMHBI5Yjtk6Fr4N1w2OgafqA057bwyyy2UsVxIHvXjiaOMSKY8Qj5snBkzVSSTdv61f6W9SVdrXf9bL9b37F7SPiXpWstpLQWGpwW2rTy21tdXMCxoZY92UILbwSEYg7cdiQeK7GvKdM8C+L7LSfC1nLDohOi6vLfzuuoTfvEcyfKo8jr+9br/dHrx6tQ7dA6/13f8AwAoooqRhRRRQAUUUUAFFFFAHN+A/+Rduv+w1qv8A6cLiszxxPrOja3ourQeIbuz0N72O21G2SC3ZVV8hHDNGWALlVbno3GMZrT8B/wDIu3X/AGGtV/8AThcVqa/o1v4h8PX+kXo/cXsDQsR1GR1HuDz+FF7a9hrXRmLfz3r+N2li8QXFnpGmWXn39qsMJjdiSVy7Rlx8qsWww/hxjJzE/wASNLtnnTUNP1WzaO0N9CslsHa6gBALxrGzHjcMhgrAHJAFN0HwXeR/D280TxPqC3upapDJHf3sIxvLJ5YIyOyBRyO1ZOn+Ar3TvDt7b2nhrwjZ6obN7SK+skMJuQy7SzkQ5i4+YqC+TxkdaUtE0tbf8H9bfL8COrTff/L89S5b/FWzubvSI08N+IFttYaFbS9lghSBjIm8As0oPAByMZ44zkZ6rTNY/tO81CBbG6t1sZ/I86bZsnOASU2sTgZHUDnjsa5HUfDl3B8E4tJ1V7e31HSbGNoZ7aRpESeDBidSVUnJReMdyOep6zw7Yz6f4ftYb0q14yebcsowGmclpCPbcxrSXKm7dP6X6/eiFeyv/Xf9PxOdh+KejzpqEw07WUs9Nkmiu7qSxZEhaNA5DAncMg4GV5IxxkZbd/FPStN0vVLvVtJ1myk0sRNcWr2qyybZQSjgxOybTtIyWGCMHHFVtL8LeLLXQ/F0In07T7/WL2S8sp7W6klERdVXaxMSleEHzDP3unHOHqvw38TT2HiKDTLTQ4Dr1pawyB7+cmJ4i25i5hJlJyvzHB9enMq1lfsvv6l9fm/uOxl8ewRxTbNB1qSeAPJJbC3RZFhX/lt8zgFD2wSxwRtyCB0Gl6naa1pNrqWmyia0u4llhkA+8pGQa4zX/AsureIbLXZ9D8P6xObJLS7sNV+eOPaSweGUwscgswOUG4Y6YrtNMso9N0yCzggt7eOFNqxW0YjjQeiqOgFGlv6/rt/W063/AK/ruWqKKKQwooooAKKKKACiiigDm7H/AJKnrv8A2BdN/wDR99TfHkesjw61x4d1qbS72N0SPbFFJHIzuqDzA6McDP8ACVNOsf8Akqeu/wDYF03/ANH31WPFtprF9o6W+g29jPMZ4pH+23TwKqo4fgrG5JO3HQdc9sFMa3OQl8WaprvhtI49RuvDviDTtRtrLVLWCOF+ZJUQsPNjbKMrFkYY984xW/f/ABA03SDOZ7bULjT7GcWt9qqRoYbeTjO/5gxxuGWRCozyRg4reKPAbeIdX0bXbaSPTtWs57drwRuWjuYUkWRomOAWwVypIHPpmqd14E1U6Zrvhy1eybRNdupria6lmcXFuJSDIix7Cr85wxdcZ6HHNrz8/wBPw3+f4rS2n9LX8dvl+Glo3i6/1P4k61oTaVcR2NhbwNHc74ShLh23nD7sMAAoAP3TnGaztV1m50P4uSvc6hez6d/YElyNPDoEEgmjUBAdoLN0G4nlsAgHFa+k+Gr/AErx/quqxSWrabqFrbRBSzecjQq64xjGDuBznsRjvXO+NvAfiDxL44TWNPNhbR2dgYbG5+3SJNFcBxIkhQQspXcu0qScqSevFLRSj8/yYatP5fobh+IcCapa6VL4e1yPVbq0ku47JrePdsQgY3+Z5e45Bxv4yA2CQKnh8fabeaRpd5pVre6hPq0TS2tjAqCZlTG/O91RdpODlhzwMmsWPRfHNz4x0vXtSsfD/mWOmz2jpBqc2Jnk2NvGbf5RuQDHOA2cnGDT8M+AvEnh3T9CvANLm1fR4rm1Nv8AbJBb3EM0gfPmeVuRgR/cYH8eDT+vn/wBa/18v+Cb1t8SdNvLnS4rTTtSk/tG6ksi5SJBa3CBi0MoaQMrAKTwCD2JzS2PxDt9QspZodC1YSw6m2mS2p+zmVJFXczYEpBUD0JJ6gEc1RufAN63hO/js7q2i1661T+2I5ju8mG4DqQvTcV2rtJwCck4GcVNovgO40DxjcapZ3Ub2M1ssjWrEgyXwUo0xODgMh56nJJxRp1/rZ/5r7h+n9br/J/eSab8TtJ1T+z5IdP1SK0v759Pjuri3WJEnUsNjKzbxnacHaRng4PFdnXk9v4F8ZQ6HpNkYND8yy8QvrEjDUZsMpkZwg/0fr+8Iz/sg98D1ijp/XZfrcX2v67v9LBRRRSGFFFFABRRRQBzfij/AJGLwZ/2GpP/AE33ldJXN+KP+Ri8Gf8AYak/9N95XSUAFFFFABXN33/JU9C/7Aupf+j7Gukrm77/AJKnoX/YF1L/ANH2NAG3qOo2mkabcahqVwltaW0Zkllc4CKOprnn8e2ttHFdappGq6ZpcxUR6ndxRrCdxAXcocyRgk9XRQO+Kq/FrRNQ1/4dXlrpMLXNzHNDcfZlPM6xyK7IPcgHA7msjxx4q0fxZ8PNS0Lw9cR6jrOp232eLTIiDcQs+BmWPrEFzklsAYpdPPsHVfmelggjI5BorxrwZoegzfE7xDp9zfrqF9pdvYSRu188rxzxo4kdQWyMM2Co4G7GBnFZfgq40vUNe0L7NfW1ve2iTPqk9vq8aXGtOATGTFFL5rsCNxWZRtGVwap2/r+v6/JK9j3mivnvSL/QIdVsb03trptjqWhXyXUn2wx3MkitGR9pnUpmcZPy4BXkZIIq14G1LQbLVPhe9lqFkt/e6XPBestwrSy/IuxHOcnEisFB6EED0pqP9f8AgX+X4g3b+vT/ADPZtd8RWHh6CBr9pGlupRDbW0CF5biQ/wAKKOvHJPQDkkCqdv4rMt1FZ3eharYXs6SSQ29ykR8wIMn95HI0YJyAAWB9sc1zvjpJdL+IfhTxReRSS6Np63MF3IiFxaNKoCzMB0Xggt2zzXTW3irw9qyC507UbPUIIFaSS8t5UkhtgF5LyA7UOD0znB6Yyaj7N/X5f1uPrb+mHg7xJ/wlvheDWBZvZedJKnkO4dk2SMnJHGflzx+Z61uV4F4f1Pw/qngfwxp13LZXkc1/qC7byVWsw/mOyrKmDvkIdWRMqTnIPAzJYXcK/Dvw3rEt9o2pTaXZSwyaZrDkea3mFR5MhJKTjYVAwxwccZzVPcLO/wDXc9v1DTLDV7Q2uq2VvfW5YMYbmJZEJByDtYEZBqyqqihUAVVGAAMACvJdUvbbT/Fllqv2XT9Qa/a0gXSboFNTsTiM4gPJdVyjuoAHDEt2r1ui1kK9wooopDCiiigArm/Hn/Iu2v8A2GtK/wDThb10lc348/5F21/7DWlf+nC3oA6SiiigAooooAqWGlafpSyrpdha2QmkMsot4Vj8xz1ZtoGSfU1boooAKKKKACiiigAooooAKKKKACiiigAooooA5v4cf8ks8Kf9gWz/APRCV0lc38OP+SWeFP8AsC2f/ohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8B/8i7df9hrVf/ThcV0lc34D/wCRduv+w1qv/pwuK6SgAooooAqXWk6de3tteXtha3F1aEm2nlhV3hJ6lGIyufardFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76ukrm7H/kqeu/9gXTf/R99XSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfij/AJGLwZ/2GpP/AE33ldJXN+KP+Ri8Gf8AYak/9N95XSUAFFFFABXG+I7+5074k6BLZ6Teaq7aTqKmGzeFXUedZHcfNkRccY4OeRx1x2Vc3ff8lT0L/sC6l/6PsaAD/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5Kp3j+4v7LwFrF/pOozafd2VpJcxTQxxvkohYKRIrDBxzxn0IrG0fxmdNh0jRdROsa9rl9pn9oiRbOJBIMKWVWAjjGC2BzxxuOSMi1v5f8H/ACYPS3n/AMD/ADRo3fiHWLqzmgXwV4kgMsbIJYrjTwyZGMjN11Fc/pUniu3tbax1jw3q19YWbRtbpBbWEEh8s5TzG+3MGwQp+VU5HoSK3NP+I+l6i2jtHY6jFbaw7Q211LCqoJlDExMN28MNjchSuRjdVeL4qaPPai8TTtYFl/aJ02S5e02CKbIUBkYh+WIXhTg8HFNJ30/r+rg9tf6/q34Gl/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlVQvfiZp+nWGq3F5pGqxyaRcRQXltthMkYlxsk4k2lDkdCWHcU/WfiTpegXms2+p6fqif2RaR3kjxwLKs0TkgMmxiQMqQS4UDGTxzSAuf8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVRwePtLa7vYL22vdPNpYrqAa6iUedAxI3oFYt1GNrANnHHNW9G8WW2r6zd6RLZXmm6jaxLOba9VAzxMSFkUozAqSCMZBB6gU7MV0Qf8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVVl/E0f9uXGmWunX141oY1uZoFjKQs+CqkFwx4YNkKQBnJrLtPiFDd6brF0NA1eKXSLpLSazlFuJpJG24CATEH76nJIznjNLcqxb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KpbPxeNRiuZbDRNSmiheSJZR5IWWSMNvQfvMrhkK5YKCcYJBzWN4T+IVxq/gzT9TvtFv3v8AUGka2s4DCWnQEksh8wKFUEDLlDkdORkEbH/CUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lVQtvihot9eadZ6faand3eoxzNDDHa4w0RIeNmYhFcEYI3YGRkgEEvsviTpd6mlyjT9ShttSujYrcTRIqw3ILDyXG/dnKkZUMuR96nYOly5/wlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRSA5v8A4SjV/wDoRPEH/f8A0/8A+Sq5/wAaeI9Um0G2WTwXrkAGraaweSaxIJF9AQvy3JOWICjtkjJAyR6JXN+PP+Rdtf8AsNaV/wCnC3oAP+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAOb/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooA5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sq6SigDm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KrpKKAPO/APiPVIPht4aii8F65cpHpNqqzRTWISQCFQGXdchsHqMgH1AroP8AhKNX/wChE8Qf9/8AT/8A5Ko+HH/JLPCn/YFs/wD0QldJQBzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVXSUUAc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlV0lFAHN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVdJRQBzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVXSUUAc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlV0lFAHN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVdJRQBzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVXSUUAc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlV0lFAHnfgvxHqkOg3Kx+C9cnB1bUmLxzWIAJvpyV+a5BypJU9sg4JGCeg/wCEo1f/AKETxB/3/wBP/wDkqjwH/wAi7df9hrVf/ThcVi+ONYuNC8ZeHWuPF0mh6RfPKl0kv2VIv3abl+eWMkFjwfm6dMHmjqHQ2v8AhKNX/wChE8Qf9/8AT/8A5Ko/4SjV/wDoRPEH/f8A0/8A+Sq5OLxlLffFC7Xw/wCJpvEGjWuk/b203SjZzbpfM2eWH2g9PmwXBz3xxXSWfxAtb/QNI1e20fVZINV3mONI4nkhRQSWdFkJ6A8LubOBjJxR9nm/rdr9A62/ra/6lj/hKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KqlpnxL0rVE0q4jsNTg0/VpTBa39xCqRNKGYCMjdvUnacErg9M54qWT4i6VBdwpPZ6kltdCT7FeLbiSO8aNSzLGqMZC2FOMqN2PlzRsBY/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrOsPihpuqabbXtjo+syQ3u1bItbpGLt2ZxsRmcKGHlkncVGMcmtW+8WpZRIq6Pqdzeukkv2CGOPzljjbaznc4TGSMfNls8A0bbgR/8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVWfD8UtFvrqG30ay1TVJZ9OOoxC3tdqvECAQGkKruBPIzwQRnOAb1v45sL+HS5NIs73Uf7TtPtsaQLGGjh4+Zg7r3IG1dxz2p2f9fP8Ayf3B/X5f5od/wlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVUrrxpZQ6h4gFjp+qXGp6Rp0dxNby7oo3U7yuwOwXPDZYDnGMnGBR0Hx3HqVn4SXW9O1aHVtVtjPAEwsMrCEszEpJ5ZBGdqMcjKkqvUCV/69f8gf8AX4f5m3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlVX0/x8mpaG2pW/h7WAV1A6e1q4txMJA20nHnY2huDznvjHNYfiD4jRaf4d8Q6j4d07U7i7stRisbgXJ2CKRtih0SVhhcMuAAASc4wS1L+vy/zQf1+f8AkzpP+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKqDT/Ha3mvXukXXh7V9Nu7Ky+2ut2bba8eSBtKTMCSQR6DHJHFc/4w8Xa02n6Pc6XY3tlDdyWsvkzR+VKpM4wjSq7RneMKYxlsNk8ZFHVef9foD0T/AK/rc6f/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqtXRLq5vdCs7m+GLiWJWkH2d4MN3/AHbksv0JzV+m9HYDzuz8R6oPiTrMo8F64ztpNgphE1jvQCa8IY/6TtwdxAwSflOQOM9B/wAJRq//AEIniD/v/p//AMlUWP8AyVPXf+wLpv8A6Pvq6SkBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBwmp6zfaj4t8HxXnhrVNKRdWlYTXklqyMfsF2No8qZ2zznkY4PPTPd1zfij/kYvBn/Yak/wDTfeV0lABRRRQAVzd9/wAlT0L/ALAupf8Ao+xrpK5u+/5KnoX/AGBdS/8AR9jQBN4203Uta8GanpWix2r3N/bvbA3c7RIgdSpbKo5JGemOfUVyum+G/GsHiXQdTu7HQduk6TJp7LFqkxMxYJh+bcbRmMcc8HqcYPpFYkPiqzuPE+o6Bb29499p9slzIph2LIrZ2hGYgMSQRn7ueM8GhaPT+tH+jYPVa9P1a/yRwdl4G8ZWOg+GbRbfQpZ9F1abUJM6lMqyq/mEKD9nJB/etzj+Edc8NbwL4zfwvd6a1voQmuPEI1gMNSm2hfOEpjz9nznKhc4757YPq8TtJCjvG0TMoJjcjKn0OCRkexIp1O7Tv/XT/JCeq1/rf/NnmWq+A/EWs3XjMTjS7eHXo7drRlu5HaOSDG0OvlL8rYySCSPQ1D4m8C+Mden1y7jk0OGTWNFj0xrZppiIiGclhLs5A35+5z04xk+p1jap4osdJ8Q6Ro1zFdNc6u7pbvHCTGpRC53P0HCnjk+2OaS6Jf1p/kPz/r+tDidV8AeIfEWtTvqkek21jcaCumMYrqSd1kVxIH2NCqsu4YwSMjn2rpfCHhddEkeeTw34c0a5KeUz6LEMzjIOWPlIVGR935vrXVUU7/182/1FZf15JL9EcR4l8HX+r+JrXU9NhsbC6iuIz/a0NzLHcCBdpMTRqu2YMd4wzAAEHBNJeaDK/wAXLe5tJlFlcWa3GpQYzukhbEDexJdvr5Q9K7iqlhpWn6Usq6XYWtkJpDLKLeFY/Mc9WbaBkn1NJaW8v6/4PqN6p+ZyUXgy/j8dR6zaR2WkxMZWvmsrmQ/2huDBRJAVCAj5W8zJYkY6VhW/wu1GLw34ettQs9A1i40HzoEtL9We3uYZDksWaNjHJwpGEYDkc5yPVaKNlb+v61HfW557/wAIdrNl4v8AD2o6LpHh6x0/TIbgSWltO8ADTBQQirBg42A7jgtk8LjnKg8C+MYfD2l2XkaGZ7LxC+sOf7Rm2shkZwgP2fOcyEZx/CD3wPV6KadmvL/O/wCYt1b+trfqA6c9aKKKQBXN+PP+Rdtf+w1pX/pwt66Sub8ef8i7a/8AYa0r/wBOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/kXbr/sNar/AOnC4qr4i0nxFe+N9B1LS7XTHsdLaVpDcXskcr+Ymw4VYWA2jkfNz0461a8B/wDIu3X/AGGtV/8AThcV0lHW4bqxxw0PxB/wto+ITb6Z/ZR0/wCwf8fknn43+Zv2eVtznjbu6c57VX8HaDJpninxCyzLJpltcuunxgH9w0wWWdc9CN+3GOnIrtLm2gvbWW2vII7i3mQpJFKgZHU8EEHgg+lQppWnx6V/Zcdhapp/lmL7IsKiLYRgrsxjGO2MUull2a+/UHq7vy/BWPKvh7oWqeJfh74atrv7DFotneNe+ZHK7TzNHM5VNm0KgDYJbcc4xgZrY8O/DqTw1GYbbw54Wnmsw5sdWMfl3UvXaJMQna2DgyBmJ67ea7vStF0vQrVrbRNNs9Ot2cuYrOBYkLdM4UAZ4HPtV2qet7Br/X9eZwGieCtRtfhXp/hjXdM0XU5LXKyQyXMhhlA3MjK/l7kbcV52nABxzWYnww1BI9Nu9RtdG8SXNtHNA9jrbtNFHE8m9FjneN3JQfLuZPmHpXqVFF9bh0seeDwjr1h4wj1HR9N0GDT4NHlsIbaK5e3Cs7iThFgKqoYbeDk8tjPy1Qg+HOsN8PdJ0TULDR5NT0u28i21CG/niktWycyxyLEG6bTs4BwQTivUqKXS39bt/qw63/rov0PPrXwf4jPibW7nUJrCW11HRYtNF0J3M7PGrjzWj8sKNxkOQGOMd88V7Pwf4strjwNvj0Z4vDkZjuCLyUM4MPlHYPKOcD5ucZJ28Y3H0minzO9/66/5sVla39dF+hylj4TurLx9f6otxD/Y90VultcHet5s8tn9NpTH4kmuavfAPibUtP8AF9vN/ZMDazqMF/ZlLuRwDEY/kk/dDbkRDkbsbuhxk+oUUlp/Xmn+iGcH400G81LVfDlxDNDBfzSvY3ioGKy2kiFpkHQ8bAQx79ucV281rb3EaR3EEcqI6uiyIGCspypGehBAIPaoYdJ0621K41C3sLWK9uQBPcxwqskoHADMBlse9W6fSwdQooopAc3Y/wDJU9d/7Aum/wDo++rpK5ux/wCSp67/ANgXTf8A0ffV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/wBhqT/033ldJXN+KP8AkYvBn/Yak/8ATfeV0lABRRRQAVzd9/yVPQv+wLqX/o+xrpK43xHq9to3xJ0C4vI7yRG0nUUAs7Ka6fPnWR5SJWYDjqRjoM8igCz8RdZutC8HSXdnMbYvc28E10ACbaJ5VR5OeBtUk5PA615xr3k6B4s8Zw6R4hvILpPC0dzayvf+fcAo0rkK8pZiOhPcBuCOMekzeNtDuIXhuNP12WKRSro/hq/ZWB6ggwcisgXXgFbF7NfCFyLWRQjwDwbd7GUNuAK/Z8EBiSB6nNLo16/lb8Nyk7NfL8Hf/gGVq2pahp1hp/iDUZb6+0WHR7c3LWGptFPZOyndO0WQJgwI+8SQV4Byah1jUNQ1LSfG2sf2tqGn6joNy402KG5eONUWJHTdCDtkEhJ++G64GK3l1HwMiWqJ4VvFWzYNbKPB94BARkgp/o/ykZPT1NWLnX/CN7qUGo3nh/U7i+t/9TdS+E71pYv91zb5H4Grk7tv1+Wt/wCvUiK5Uk+lvnY5lG1y+8ba4brWNXD2WjWWpxafBOI0Sf8AeM0W1RypKbSDkkMcngYyZb62W8+G3iSbXJry61CWWWb7TekxPM1q42pGTtjw52BUA5IBya7qDXPB9trEurW3h3UYdSmBEt7H4SvVmkBxkM4t9x6Dqe1Nt9X8F2l615aeGb+C6eQytPF4RvFdnPBYsLfOeevWlft/W/8AwPuD8f8Ahrf16nJaF/wmOsabYeIBrMVhbXtnKL9o9YluJHl8skeXbyQeXA6MpBVTjGc5IzU+h6br9/8ADbw7q9rrGp6reX9vbzXtjPq727XSrG5IhkXDI+WUnBAYIMnkk9G2peB3mvJX8LXrSX67btz4QvC1wPRz9n+YfXNOXVfBSaSNKTwxfLpy7sWY8I3ghG773yfZ8c5OeOc0X0dvL9f8x9Tc8Havba54Xt76y+2CN3lVkvW3SxusjKyE5IO1gQCCeAOTW5XLW/jPQbO2jt7TTdcggiULHFF4Zv1VAOgAEGAKl/4TzSP+fPxB/wCE5qH/AMYodr6CWx0lFc3/AMJ5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xSGdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lc348/5F21/wCw1pX/AKcLej/hPNI/58/EH/hOah/8Yrn/ABp400u50G2SO11wEatprkyaBfIMLfQMeWhAzgHA6k4ABJAoA9Eorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAD4cf8ks8Kf9gWz/APRCV0led+AfGml2vw28NW8trrjPDpNqjGLQL6RCRCoO11hKsPQgkHqDXQf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQAeA/+Rduv+w1qv8A6cLiukrzvwX400u20G5SS11wk6tqTgx6BfOMNfTsOVhIzgjI6g5BAIIroP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKAOkorm/+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKACx/5Knrv/YF03/0ffV0led2fjTS1+JOs3Btdc2SaTYIANAvi4KzXhOU8ncB8wwSMHkAnacdB/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAHSUVzf/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQB0lFc3/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8ACc1D/wCMUAdJRXN/8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/AAnNQ/8AjFAB4o/5GLwZ/wBhqT/033ldJXCan4lsdZ8W+D7ezg1SN11aVybzSbq1TH2C7HDyxqpPPQHPU44Nd3QAUUUUAFc3ff8AJU9C/wCwLqX/AKPsa6Subvv+Sp6F/wBgXUv/AEfY0AW/Fnia08IeGbrWb9XkjgACRR/eldiFRB7liBWW1z45g01tSlh0edvLD/2VDDKJI+mR5+8hyOePLXPTI61Y+IHhM+NPBt1pEVyLW5ZkmtpyMiOVGDKSPTIwfrXKeMdL8QeOfBUnh7WPBY/tNgvl6g1xbSWkMgxmRGL+aMjI/wBXnnHTmiP9egPp2OzvvGmgabrC6Ze3zR3JkSJiIJGjjd/uI8gUojNkYDEE5GKl/wCEp0o301oktxJLC5jYx2czIXCliiuF2swCnKgkjGMZrzzxD4S1+WW+tdN0ArZ29/YT2Eeny29vBJDC0e4Ou5WaQBWAD/IFC7cEVvQaLrVn46gu9CtNQ02xurmWbVYri7ils5VO4Bo03F0lYhW+UKvJySadtP68rfqH9fn/AMAXQfi34d1LSba71S5fTJry7lt7W3uLaVHm2yFV2gr85wFztyAxwcHitab4h+GILKG7fUXaCWFZy8dpM4hjbIDy7UPlLweZNo4PpXB2vhvxTY6L4V0x/DVxP/ZPiCS9nliurfaYvMlIYBpAeRKpA68NkDAz093pGs6X4j8SzW2lS6xbeIY4hGyTRILVli8srIHYHZ0bKBjyfl9U9m1/Wi/r5D+1b+t3+n5mvN4z8NwapeiXxHAv2CzWe6g3KYoUYgrIzbcgkMABu5BHHenWXj3w9qOBp95LcM1l9uiVLSbM8Ixlo/l/eEZAKrkgnBANef2vhTxF4evrmztdAvdStovCsejRXcU9sgmmXcSwV5QwX58ZIzweOhN7QtF8Rw634IN14cvIIdK0SWwvJnuLYrHIyxqOFlJI/dZyAeGHuA2lZ2/r4v8AJfeT11/rSP8Am/uOj8O/EfS9Z8IW+u3KXdstxI6xwfYZ2kfBJARAhaX5QCSgYDn0rSXxx4fkt7eaC+a5juImnVra2ll2RrkFn2KfLAKkfNjkEdeK8+03wV4gtPC/hZb7Sb6R9DSe1uLKw1b7LNMsjAiWOSOVAQNo+VnGQxzggA3r/wAFXOmaekvgnRdW0jVFUm1nh1NJMNI7Oy3QmkYOob5jjefnO3nmnpcdtDaufiZpEHiPXdK1Ka40u20u2iZ9QltJFRXfdzvZCg6Jtz94k4DYrSfx94aspo7GXWDc3gsheGKKB5Z2iwDvMcaZyQwOAAcZOMA45PxD4f8AE32rxq1tozaide0eC2hkt7iJF80RyIwxI6kYLg+m3PJPBTT7LxJD4o07UJfCWorDa+Gm05/9JtCTPlWwP3/Q7cZ9SOg5qf6/CX6pfeHVf1/L/m/uOxvvHvhvTrC1vLjUS1vd2/2qJ7e3lm/c8fvWCKSiDIyzYA7mqMWvajL8WINLjvYZtGudFa9hjjhAO/zEUMXydwwTjGBz361wlj4T8Xt4KstEuvD89ts8Py2BaC6tkk8/LYEkgct5RG0gIepO4dMdHoGna/D8QNDvbvw7eW9nbeHhp09w9xbMI5so/RZSxHykZAPJHbmrSXP5a/lK35L7xO/L/XeP+b+49IoooqBhXN+PP+Rdtf8AsNaV/wCnC3rpK5vx5/yLtr/2GtK/9OFvQBv3S3D2kq2UscVwUIikljMiK3YlQylh7Aj6iuE8MeONWv8AVb3w74jWysdXdpzpV5HA/wBnvUjdkJEZkJ3KVyyb84IIPeu+ldo4XdI2lZVJEaEbmPoMkDJ9yBXBL4XuvFXg2Wz1TTrzw/qdrfTXenXUkkLyQSNK7pIpidxjDAMpxnkcjmj+v+G8/wCvMfT+v6sXNJ8aNp/h2G88ZX1s9zcyzCGLTNOnLFImKsfLVpXOMZLcAAjPqdSHxx4fuLxLW1vJLiWWwOoxCG0mcTW4x86FVIc8j5VJbnpXHQeHvFcWl+HrS+08TMlvdx6hPYTRRypLI+RiRiGWJuSfLO/IX0IqLwz4c8R6HL4PvZdCmkksdEl0q7gFzDmBy0ZWQnfgodhztywyPl7U+9/60f6pfeStl/Xb9LnaW3jrw/eWNjeWd3NcQ36NJB5VnM7bFOGdlCZRQRjcwAzUupeMtC0iSNNQvTF5iqxcQSOkSt90yOqlYgexcrmvOtL8G+JbDwLpsL6XfWPiLT4pY7S70jUojjzJC+2ZZNqMgOMjD+q81oXngi+u9evz4l0m/wBctdZhg89tO1iS1gikWJY3SSHzkDRkruDAMeSCOBk6jOzuPG3h+11xNJmvyLpplt8iCQxLKwysbShfLVyMEKWBORxyK3q8m1bwx4kn1BhHokpis9bs7y3FncwxQTQRlAzEFg8koCnJk4wF28ivStO1UahcXkDWlxay2kvlssxQ7wRkMCjMMEc4OG6ZAzRpy3/rZf5i1v8A15lCPxpokuparYRy3ZutIj828j/s+4+RecEHZh84ONuc4OM1FdePvDllbRXFzeTJHJCs7H7FOTBG33XlATMKnB5k2jg1neJPDuqT+NLLUNGiVrXULc6frBMgQrCDvSQDqSMyJxz+8z2qvdaPrGleIvEktppUmr2viCOJY2jmiRbVli8srIHYHZ0OUDHk/L6z9m/X+vzKsuby/r/g/gbN34/8MWd7cWb6qk11bW4upoLWJ7h0iOCH2xqxxgg/Q56c1NaeNfD99fQ2ltqId7i3NzBIYnWKaMDLFJSuxsA8gEkdwK4PRfDGv+GNeaGLQr3ULO18MRaVHdxT2yieZCzHCtKGCndgEgcj05pmh6L4m07/AIV39o8L3x/sGymgvttzanYzRiMY/ffMPlzx2I78Vdl3/r3v8l95Ov8AXov82vkdBe/EzR9P0vSrvTry81y31bUzaxXMNm8qqA53qPKjG7aAQoAJbGfmwTWiPH/ha0sNV1W48SxvY2dyIJmkAC28m0fulwgLHuR8xySOMYHF6b4Z8Tr4d0cTeHriG507xTJqb28lzb7pIJHlbKlZCuR5gyCQeDjPGY9X0LxXe+H/AB7aR+FL3z9dvo5bMfa7XayhI1JJ83j/AFZPIzhhx1wlbW/9fD/m/uKfxf13l/wD0i28YaFdHUBHfiP+zYxNdGeJ4gkZBIkBcAMhAOGXIOOtGleMtA1m9FlZaigviu8WdyjW9wy4zvEUgVyuP4gMH1rz7xLp2qXer+Jr7UfDd7Fp1/4ehsYme6tgzzhmIQBZGOSZAo4ILD0wTqeGTrFh4gutW8TaXqkmqz2C20CrBawRzJFl9oVbqUeYdxO52VewxRp1/rf+vmT0/ry/zf3HpFFV9PvY9S023vYFZY7iNZFDjBAIzzirFLYZzfw4/wCSWeFP+wLZ/wDohKx7bU/G+oeLtf0m21PQIY9M8loWk0qZzIsqlgGIuRgjGCQDnrgdK2Phx/ySzwp/2BbP/wBEJWFZXPiLTPHHiXUz4K1W4t77yEtWiurIb/KVlLNunBUEnjgnHUA8UdQ1H2/xGtV0vXLbxhcx+GtR0idbe5kgkEo+dd0ckW5Du3DOAVJyCMGug1PxroGjagljqN+0cx8sMwt5HSLecJ5jqpWPcem8jPauB13wV4kufCXi+/l01b3xB4neFBZWc8YS1hjwEBkkZA3AJJHduBjmn+LNB8U6+mrCLw/cos6Wc1qkNzbRBzGyM6TkPueQEMACTHgDBz1fb5X+5X/rYH5ef9f101Ouuvif4Lsrq4t7nxBao9rP9nuG+YpDJhjtdwNqn5WHJ6jHXiue134nWlxqXhp/C+uQNYXWoQRXqtZvukilVyhR2AHJjZcAE54yCMGxo1prsGueOdQuPDN9CmqeW9kjT2pabZCI9vEpCkkZG4gY754rJt9B8SW/gv4d6efDV41xol5DLfotxbfuljRkJB83DZLZGM8A5weCR6N94/jv9wPZ+kvy0O9g8aaDcaPJqcd6/wBnjnNsyvbSpMJh/wAsvJKiQv6Ltyewp9p4v0K90q41GC+AgtpfJnEsTxyRSZACNGwDhjkYUjJyMDmvPrXw14mfxDfaw+h3UK2viM6tb2slxb5vImt/JKqVkIVwRuAbaORz1xb1TwRq2syazrqWc1nc315ZXCaZ9s8mV0twQQ0sL4R23HBViBtXnk4XRP0+W1/uu/uB729f1/4B16eOvD0mmPfLeybEuPsrQm0mFwJsZ8vyNnmb8c7ducc9K09G1rT9f0uPUNIuBcW0hZQ2xkIZThlKsAVIIIIIBFefv4XvLOO2vvD/AIZ1C1kutQil1IXmox3V/tRHQOkk0siKeVGQ+7YWxg4rS8EJf+ENCXTdY0i8j+0axchJvtEUwCyzM0bsxk3tncB0LZySAOaqy/r5f5ie39ef+R3lFFFSMKKKKACiiigAooooA5vwH/yLt1/2GtV/9OFxXSVzfgP/AJF26/7DWq/+nC4rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5ux/5Knrv/AGBdN/8AR99UPxH1zWPDXgm81rQHsRPZASPHe27yrKpIGBtdCpyc556dO9TWP/JU9d/7Aum/+j76qfxTsdV1b4e6hpWhaVPqV5eqI0SKWKMR8g7mMjrxxjjJyelA47ko8eaPpPm6dr+s21zrFlbi4vYtOs5WMaHHzeUvmMAAQTyeOTgU25+IFhF4y0bQ7eK6uE1S1a6S6htJZIymVCYZVIwd2Sx4UYyRkVzkkHiS78Zarq58H6nDDceHxp8SSXNmWaYO7Y4nIAO4c+x6VF4e8L+IrV/BclzpElubDQptKvA1xFut3PlgSfK53KRGSNuTyMgc4a11f9fF/kvvJ2Vv6+z/AJv7juIPGvh+41CSyTUAsqRPMGlieOORE++0cjKEkC9yhOO9ZniL4jaZo/g7UNbtIb24a1hDpE9hPGWLEqjEMgIQlT83THfkZ5rw74BFpp9ra614Z1C8vtItpIIrm51ySW1uQYjGfKjaZvL3jgq0ahc8E4FM1Dwl4oufB/inQrGO/fTJLVI9LtNWu4pZvMVssEkVm/dkBQvmNuB9BRZFLc7KHxnoM+q7G1treaDT2u7ixuITD5UWV/eyB0DxkZ4BIyCTg9RJpfjzw3rV1ZwaZqXnm+R3tZBBII5gn3wshUKWGMlc5xzjFc7PF4hPxLh1r/hFb57OPQ5LQtHc2pJlZxIFwZQei7Sem49SPmrn9G8P+K7HR/h/ayeF7oS6HNO14WubUom+N0U8S5YZcE4GcA8Z4o0t/Xd/8Albf12X63R6Bb+M9I1yS407QdSUagbd5bd5rSXy5AOPMQsFWZQ2M7GP1FN+HOs33iH4eaRq2rSLLeXUJeV1QKCdxHAHQYFcXoeheKLDXNF1a/8AD148lrpd3aXMEFzarGkjFGQQxCRUWM7SAeG6b+ma6z4Xadqej/DnS9L1zTpdPvbNDFJFJJG+75idwMbMMc98HjpTsrf13f8AwBvf+vI66iiipAKKKKACiiigAooooA5vxR/yMXgz/sNSf+m+8rpK5vxR/wAjF4M/7DUn/pvvK6SgAooooAK5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6PsaAOkrLj8S6RNrF9pVverPf6fEJrq3hVneJTyMhQeT2Uc+1UfHGvz+HfDX2qyCC4nuoLSOSUZSIyyrHvYdwu7OO+K891Z9c8N+LvGV3aa213qFn4YhuYbu9tY2bCySsVKxhFPQgHHGRkNjldL9NfwVylG+i30/F2PYopBNCkiBgrqGAdCpAPqDyD7HmnV5vqXifWNPXS9R1e9v7HRZtMhdtQs7SKaJbhwd5uAVLogypBXavXJ6VFqvibX7zS/FuuaRqv2NPDVzJHDZG3jeK7WOJHbzSyl/myQCjLjjrVyVm/K/4O36kR95K3W34nptZt74h0nTtasNJvL6OLUNRLC1tuS8u1SzHA6AAHk4HauAXxH4ovfFWr/8AE3S0sLDSrTVks4rBWcq29nhZmJJJCEbhjBIIAwc591d6pc618OvEOpaq16l9JNdm0SGNY4CbN2CxkKGIxkHeWJPPHSla2/Tf8f8AJ/cCae3bT7r/AKo9horybSPEvj7V7ey1eytrmHT9SsXmllvks2t7RjHujaFYpfNcZ4IfnnPy8ipNM1TxtdfD7RfEL6peagmowwS3kWm2MH2i2TY5Z4gwKuSTHlSpOA20cgA5Wr36f8H/ACH6HqtFZXhnVbfW/D8F/Z37X8UpfEzxeU3DkbWTA2suNpGByK1aGrOwlqFFFFIYUUUUAFFFFABXN+PP+Rdtf+w1pX/pwt66Sub8ef8AIu2v/Ya0r/04W9AHSUVHco8trLHFM8DshCyxgFkOPvDcCMj3BHtXlGl+KPE114c8BX0mtyfadU1CWzvVe1h2TgCYqzAICCDGv3SuefrRu7f1qHS/9aHrdFeR6d4o8Vjwbp3iS51pbqY602nT2Is40hmja6MAIwN4YcEfPjAwQfvUtv4n8WR+D5vEd1ra3E2n649jJYx2cccN1ELkQ45BdW5yuH9ju600rv8Ary/zQPT+vX/JnrdFeXt4n8Z6trM114d0++ktbTVXspIn+xLaGGN9kjszSCcSDBYYAHQYPWtP4e3vibW5b691zXoriKx1K7sWtYbFIklCMqq+cllIw3GTw3PTNKOv5/l/mEvd++35/wCTO9rK0XW9F1Wa/t9CuredrG4MV0LcfKkp5IJAwT64zz1rhvHfijXNJ1S+n0jVX8vTpLRTZ21skkYEjgP9pd1yCQw2rG4bHJGCKoTy6rY6j8S9X0bV2sJdNu47oR+TG8c+y0Rikm5Sdpxj5SpHrQmrNv8Arb/Mdm3Zb/8ADnqWqarY6Jpc+o6tdR2lnbrulmlbCoOn86ksryDUbCC9s38y3uI1lifBG5WGQcHkcHvXmOu67qvizQfFqW98+lQaXpKlrVYUYzvLbGRvMLqSEAYKNu05BJJ6U/w3qWs63ZLo2katJo40bQ7CZHjgjk8+WSJjh/MVv3YCgYXac5+YUbc1+lv1/wAid+W3W/8A7b/mepUV5P4f8W+KPFmsaVG2qJpVtqPhx78x21ojSRzCRU3BpNwIJyQCuMHHJwwf4e8XeIbxfAmo3ep+aniESwXVp9njWJWSJ2Ei4G8NlOfm24PAFVyv+vVr9B/1+Cf6nqEFwlx5nlrIPLkMbeZEyZI9NwGR7jIPY1LXkI8XeL28P2839sWouR4tOkTyCwGHh80IAq7vl6HOdx56jGa0P+El1uFtf0iXXSJbLWoLOC8e2Rrl4pIlkKRxpGUaQZO0lMY5boTUrVX/AK+z/wDJIHo2vX8L/wCTOy8U3nhxLO303xVLb+Vqc6W8EE2SZpSw2hQOcg4OR065FTaf4Z0vTYnjiinuA6lC1/dy3bBTjKhpmYheBwDjivMrrWNS1jwlpX9tSyTXFn40htBJPGiSsiT4UuI/k3Y67cD2r2Omvh5vP9E/1BvW39btfoAGBgcCiiikBzfw4/5JZ4U/7Atn/wCiErT1zxBpXhrTvt2u30dlbbxGHkz8zHooA5JPoKzPhx/ySzwp/wBgWz/9EJXn3jvUtT8S/D/xNqI1JrezsdUFiunLChVljuI1LOxG/eTkjDAAEZB60LV2/rdL9Q6X/r+tD2XrRXnOo6tregeL9XsL7Xbqe31DTWn0RDBAvlT7trRgiL5mBePbuzwTkNjNSXWsaz4e8RQWviTVtSisGFvDbaitlA9tcSMVDicqm6N2bKgjagDDqaa1t5h/X5f5/mehUV5IfEvi2Lwt4h1+bXUlm0HWJbcWcVlGkN1EjIpQ53OCcnaQ+cnnd0qyfFHjTWNWmvPDunXzW1rqjWckMn2IWhhR9kjsWkE/mDlhgAdBg9aS1tbr+tv8wel/LT7r/wCR6lRXklv4n8WR+D5vEd1ra3E2n649jJYx2cccN1ELkQ45BdW5yuH9ju61u6fr2rJ4rn0rXb+906/up5xp8U9lG9lPGobZ5UigMW27WZXfdlTgAUdL/wBbJ/qGx3Ntcpdw+bEsqruZcSxNG2QSD8rAHGRwehHIyDmnNDE8qSvGjSR52OVBK564PavLtK8UeINX8F6C0+ttDqF9c3izNYWiNczCKR1URRsjRqowu5n4Ax82Tmux+H2s3viDwBpOqaqVa8uIczMqBcsGIzgcDp24p238hHR0UUUhhRRRQAUUUUAFFFFAHN+A/wDkXbr/ALDWq/8ApwuK6Sub8B/8i7df9hrVf/ThcV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/8lT13/sC6b/6Pvq6Subsf+Sp67/2BdN/9H31J411y70iHSLXT38mfVtSisRcFA3kKwZmYA8ZwpAzkZI4PSjrYOlzT1rxDpPh23hm1q+is0uJlgh3k5kkboqgck/StKvF/G2paxHZ634Z1S+bUlsbvSrm21CWJEk2y3QGyQIqoSChwQBkHp3rpLzVfFena9r+hafeSazOmnxahZu8UKTRbpWR4hhVRjtUlNw68Emn0v6/kn/mHX7vxdv8j0KSRIlBldUBYKCxxkk4A+pJxTq8b13VJ9fXwzFZ+Jdahmj8RQ2l1Dc2kEFxA3klh5imLazAruBA2Hd0OARbv9S8aXNz43jt/Ff2NfDpWW2+zabCTKptzJsbeG5yV5HocAZwJbtFt9Py0/zGk3JJdf8ANr9D1mgnAya8qvvGmuaPNoOoyXst5b3Xhi41G4sTFEFkmijjYMGCbhkucjOOmAKn1+HxV/wrvVtUfxQZ7O50GS6Jihjjkgn2bwISqf6oruB3FnHGG7hzTgn5X/X/ACCn7/Lbr/wP80ejm9hDWwUvILo/unijZ0PylsllBCjA4JIB4A5IqevNLDUdb0O6+H+nrq73Wn6hbSC5Sa2j819tuXUb1CgKOAAFB45Y81Wh8W+In8L6H4zj1Eywanfx20ujvbxiJIpZvLUowXzPMXgnLEHngdrlG0uVd7fjZERlePN5XPVKK8htfFfiuLS01W/1tJ2t/FX9kSW0NnHFFNCZhFznc4IzuBDD0O6vXqm14qX9bJ/qU9G1/W7X6BRRRSAKKKKACiiigDm/FH/IxeDP+w1J/wCm+8rpK5vxR/yMXgz/ALDUn/pvvK6SgAooooAK5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6PsaANrU9LstZ0yfT9Vto7q0uF2ywyDIYf571zkvwv8ACM6zfaNNmmlnthaSXEl/cNM0IJOzzS+/ac4IzyODxxXW0UAc8fAmgPp8NjJb3UlpCqoIZL+4ZZEXO1JAX/eKMn5XyPbgVNeeD9Dv9Ra9ubNjLJjzkjuJI4p8DA82JWCSYAAG8HGBW3RTu73FZJWMa28KaRa+JLvXoYZ/7QvIhFO73kzo6DovllygA5xheMnHU1Qg+G3hK3ntZU0hX+xzm4tYpZ5JIrdz3jjZiqDPOFAGcHFdRRSGc/H4G0GGO7jgt7mGK73b4Yr+dI0LZ3GNA+2InJyUCnk+tSWvg7RrHQbbRrOK6gsrQFbcJfziSIEEYWTfvAwSB83HbFblFHSwFTTNLstG06Ox0yBYLaLO1ASeSckknkkkkknJJJJq3RRRuAUUUUAFFFFABRRRQAVzfjz/AJF21/7DWlf+nC3rpK5vx5/yLtr/ANhrSv8A04W9AHSVy0nw88LRKs39ifazbXLX0EEkzyKkxySY0d9iZJJwMLnntmukuZ1tbWW4kWRkiQuyxRl2IAzgKoJJ9hya5PTPiXpWqR6VcR2Gpwafq0pgtb+4hVImlDMBGRu3qTtOCVwemc8UddA6a7GR8OPBZsdJ+1eJNBu7XVLa+ubiGGe9WWM75HdXSNJWiD7W27iA3B5xzR8PvBhSO9u/E+gXdleDVri9gjub1ZImEkhdH8qOVo96ggbiMjsa3LH4iabf6nHaJp+pxx3Ec8lndNArR3YhOJAgVi+R2DKue2apaf8AEjQV07RWsrTWpl1u5nitFkgkkfejPuDM7HbypwpPA7KAcNPqv6/qwnqte/8An/mb7eEtGOtTaqtvLHdTkGfyrqWOOYgYDPErBHYAD5ipPA54FP8AD3hbSvC0FxDosVxFHczGeUTXk0+6Q/ebMjNgnqcde9L4c8RW3iXTpbq1guLZ7e4ktbi3uQokhlQ4ZW2sy/iCQQRUut63a6FZpPdLLK80qwW9vCoaSeRuiKCQM9eSQAASSACaWw9/67GdqngPw5rF1e3GoWMjyX6ot0Eupo1lKY2sVVwN4wMPjcBxmpLnwToF3qBvbixZ5X2+cPtEojuCoAUyxhtspAAwXDHiqcXxA0+W1/48NRTUftjWI0p40Fw06pvKA7/Lxs+bdv2471Vl+KWiQW8TXFpqkdy2oJpstn9kLy287EYEm0lQCGBBDEMPu5pq+iX9f1dA/P8Ar+rfga2r+CfD+uX0l5qVizzzW5tpmiuJYRPEQRskCMA4GTjdnHbFRnwF4aW3tobfTfscdtH5KLZXEttujyTsfy2XeuSTtbIJJ45qsnxAsHgugdO1BL+2vxp505hEJnmZN6gHzPLwU+YEuB+PFVNe8balYeJPDWnWegX7JqdzMkwYwq4EaP8AKA0gHUB85wVHGScUJdP67/r+IPTV/wBf1b8DTn8BeH59YGqG3uobtbX7GjW+oXEKpDjGxUSQKo78AcgHrzVeD4aeF7aDS4be1vY49JdpLFV1W6HkM3XH7z6jB7EjoTVKT4keH9Oj1a8eDWSLfU00+4VraV8TMqhdqMf3aHK84UEnIyWybsnxC021OpRalY6hYXeniNmtJ40Mk6yPsjaPY7KQzfLyQQfvYo16f11/W/zDy/rt/wAAiX4V+E1hEK2uoCMXf20L/bN5/r8583/W/ezznrmpm+Gvhd7m6uHtLsz3dyt3LKdTud/nLwrq3mZQgHGVxxx04rG8QfE2a18Oz3Gl6FqC39vqkGm3VrP5CvbtIyYOfMKNuVxt2sRlhkgZrWs/G2jG+1+a7i1LTpdHtoZNQW9DBI1IcgIoYqTwcsgw3GC2BgV7X/rp/wAD8A/r8X/wR1z8NPC11GY5LO7WP7Yb7ZDqVzGouOP3gCyDDcA+x56k11QG1QBnAGOTmuSk+I2nWktxDq2m6rps8Vq15FDNbiR7mFSNzxiJnzjIypwwByQBU2h+PdP13UNPtIrHULQ6nY/b7KS6jRVnjG3cBhiQy71yCBnqCRzQr2sv6/q34B5/1/Wv4nUUUUUgOb+HH/JLPCn/AGBbP/0QlJqfw88L6xdXk+oaZ5pvipuohcSpFOykFWeJWCMwwPmIzjjOKX4cf8ks8Kf9gWz/APRCVy+s+KtV1rxfrOhaBq1/okul20ckUp0R5Y5n/eGQStJHgJtQBSGTcSSC3Sk9NRq50V3oMWr69o8T6I1nY+HrjzraZzFskIjKIIlRiQo3ZO4LyowDWlfeFtI1G9W7vbeWZ1mE5iNzKInkUKFZot2xiNi43A4IyOea5/QPiBZW/wAP/D+qeKbxzfahp63Ugt7SSViAoLvsiUlUGRlsADI5qef4jabH4ys9Ggiu7mC401r8XVtYzzKy5XZtKKcggsSemdozk4q2mpW66/f/AEvwJW1/L8P6ZjeCPBhm1DWrzxV4evLOSXWZdQtUuL1XhkViChaKKVkLqVzll44wfTsH8K6OuszaxHaTC7lw0yQ3UiRzsBgF4gwjdsADLAngc8VWtvHnh28i0eS1vZWTW3aOwkNnMFldc5UkoAh+U8MQTg4rK8HeLbl/DuqXniu9SaW01e5sUa3tWBkEbbVVIl3MxOCdo3H60ttNrL8rL79hvrLu/wA7v7tGZ/w+8GFI7278T6Bd2V4NWuL2CO5vVkiYSSF0fyo5Wj3qCBuIyOxrrW8IaM18LtoLhplV1jJvZiId+dzRrvxG53Eb1AbnrVQfEXwmVsf+JzCJL+R4reAo4ld0+8hjxvVh0wQDnA6kCrEfjXQZdFXVY7x2tnma3VBbS+c0qkhoxDt8wuMH5dueOlLp/XoHW/V/8OU7L4beF9Pt7SGzsrmNLKV5rc/2jcFoy/3wGMmdrYyUztJ5IqzYeErXRZ9Ni0IzWVjZGQmEXszqwfJKeWzFcbjkE5K4woGTTv8AhN/D7aLDqkV689tOWWNbe2llmJU4ceUqmQFf4gV+XvitbTtRs9W06C/024jubW4QPFLGcqw9aeoFmiiikAUUUUAFFFFABRRRQBzfgP8A5F26/wCw1qv/AKcLiukrm/Af/Iu3X/Ya1X/04XFdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76tnVNKstZsHs9TgE8DENtJKlWByGVhgqwPIIIIPSsax/5Knrv/YF03/0ffVN4x8Qad4d0IXOsJfNbSzRwZsVfeGZgFyyEbBnAySBzjvigCRPCGhrpNxpslkbm3uWDzm6mknklYY2s0jsXJGBgk5GBjGKdZ+FNHsbOW2gt5SJnR5ZpbqWWaRkOULSsxc7SOMtxXOWmrzab8UvFQ1TVbhtLtNKtrwRzMPLtgTLv2gAcYQHnJ9+gqTU/ilp2j29++o6Nq8E1lbC8Ns0cPmS2xbb5yfvMFQeqkhxnlaer+f8AX6B1/ry/zNU+A/DrWa20ljJIFu1vfOku5nmMyjAczFy5IHHLYxx04qbTfBuiaTfald2VtMJdUGLwS3c0qS8YHyO5UYHAwBgcDjiqV54+07TtavtOv7O+gNnp41Hz2WMxzRFgvyYctu3HGGA6enNXZ9fnXw/d3raZd2NzHGBFBd+Xl5G4RQyMynLEDgnrSd7f16fpYL3dv67/AK3Ktn8O/CtjNZTR6QksmnxtFavdSyXBhRuCq+YzYGOAOgGQMZNWLHwToGn6fcWFtZyGyuI2ia1lupZYkRgQyxo7FY1IJGEAFRadr6w3L6NBZ6lqLaaIra6vhsZfNKqcNucOThgxbbtAJ5yMVnp8S7B9GtNSOk6rHDcap/ZLhlh3W8/meX84EhG3dxld30p2vpvf9f8AO/4htqXv+Ff+HRc6VcC2u1l0cYsmXUbgeV25AkwxI4JbORwcjirMHg7Q7bUjfQWkiSeY0qx/aZfJSRs5kSHd5aOcn5lUHk88muK8LeM5tBtdbPiJtX1K0g8QT2japII3S1TKKm8AqQuT/AhAzk4qfxj4oivfBvjl/Dt5q2nalosQ86Y7kw6ruURq+cKQOWULkEEHvSu2k/n99v8AMEteXzt9za/Q2z8LfChsDZG1vzbm7+3FP7Xu+Z858zPm53Z5z689a3dM02Wyv7+d7iVorl1ZIXuZJgmAcsC5O3PHyrhRj1JNY2oeNrTQdODXNpf3wtLSO4v5bVFcWsbA/vH3MCfuscLubAziq83xM02Kx1+7TTNSnj0FI5bjyhCfNidd6yx5kAK7fm5Ib2zxTel1/XT+v+GEveSff+v1/HzOzorAt/F0F5qJtbHTr+6EawmeaJY9sBlClVYFwxO1gxKqQBnmt+i1h7hRRRSAKKKKAOb8Uf8AIxeDP+w1J/6b7yukrm/FH/IxeDP+w1J/6b7yukoAKKKKACubvv8Akqehf9gXUv8A0fY10lc3ff8AJU9C/wCwLqX/AKPsaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/wDYa0r/ANOFvXSVzfjz/kXbX/sNaV/6cLegDo2+430ryD4eaHq3iP4e+GYLj7BDo9leNeiVJHeeZ45nKIU2hUAbBLbjkDGBmvXLm2gvLWW2u4Y54JkKSRSoGV1IwQQeCCO1VtK0XS9CtWttE02z063Zy5is4FiQt0zhQBngc+1C3v6fgD2scBpvgnxTZ6/o+tXo0m+1CwF3HcXEl7Nvu1kHyNkxHywCAPLGVUdCelVNH8C+MrC18LW9xb6Gy6Jqc97K6ajNmVZfM4ANvwR5p6nnaOmePV6KadgepwHhy08ReD7XU31Oy0ud9U1p7pIrW/kZgkp5VQYRuZcDjgEZJK453fGPh+81y10+fSZ4YdR0u9S9thcA+VIwDKUcjkAqxGQCRwcHpXRUUui8rfha35B1b73/ABvf8zkNW0LXdWuNG1to9Pg1bSJpJYrMXMjwSK8ZRlMvlhgcEEN5fGMYOawdX8B+Ibub+0bSPSjqF5rVtql7HJeSJHEtuqqkUbCIl84OWKr16V6bRTTs7r+tb/mg3Vn/AFv/AJnnMfgvWrnUPE7a1pGgahY6zeJcx20t5KcBItigt5PyNlUbcM4yQOgNOs/A3iG0XwtOdQtrm40e7uZXS5nllEcUyMqxrIRuk2AgAtt3AdVr0SihO34fgD1/rueMeMdD17R/D/ie81OPTY49W16wurUwXUkhUiaFArgxr2QHgnqR2zXTar4S8UatcajrK3Vjp+rXFvBZwwW1zL5YgSUvIpnCK6mQEjcqZXtnrXZatoWka9bpBrul2WpQxtvSO8t0mVWxjIDA4OD1q7FFHBCkUKLHHGoVEQYCgcAAdhQtEl2/yS/QHv6/53PL5fhvrX9na5BappNt9s1az1S2jSeTaGi8svG58vIyYz84yTnJAqzd+Ate13VPFy602nW1lr9nBBFNaXEjyRPDnaxRowMEnJG7jGOc5HpNFF+n9bJfog63/re5wGreFfEWuyf2hfwaVFqFnp9xZWUUV5IYpTMFVpZHMWUwF4QK3J+9UGh+EPFFhrng+4vIdIFtoWlPp9wYr6VncsEG5AYQOkanBI+8R2yfRqKE7f16/wCbFbS39dP8kFFFFIZzfw4/5JZ4U/7Atn/6ISsJYtei8a+LL3/hF9Qe1vrGKC1lW4tf3rRCQdDNkBt4xkDvnFbvw4/5JZ4U/wCwLZ/+iEro2YIpZyFVRkkngCk1dNMaPIdN8N+KV8K+H9JutAuLdbfRJbC4aC5t0mSXAADShywhbGcRndkDI4rU8L+Hdf03XfC15daQ0cdt4cGl3e64izbyq8ZycMdwIU4257Zx1rutE1/S/Emnm/0O9jvbTzGiE0WdpZTg4PfnuOKNc8QaV4a077drt9HZW28Rh5M/Mx6KAOST6Crcne76/rf/AOSf4EWVrdv0t/keZaf4W8V2ekeE9Mi0JSfD+syTyzTXsapPCfNw6bdx6SDhgDnjGORFaeEfEdzpMkt5oWoW0lr4judUWzTUkgluoZg4wksM3yOobOCyg9M4JNex9aKV/wCvu/yKev8AXr/mzyubwrdafrXhu58P+E9Tit49XfUb8z6lHPMpaBoiztJOxLZYHCswwuc5OKqaR4e8VWmrnXD4duEe11+7vhYy3VvvuLe4j25QrIVEi46MVHPBr1+ora4S7t1miWRUbOBLE0bdccqwBH4ii7vf+un+Qmk1Z/1v/mzz/wAQeG7y+1bStct9Bv0gjjnjuNL07UxZXQMrIxk3xSojNuQhl8wg5BySMVv+H4bPwtb6d4fstHurG2n814c3AnWNiS5R2aRnLHkk4Kg8bumemrLu9a0Wy8R2Wm3Vzbx6tfowtocZlkRQWPQZCjB5PGfehPov6/r+tBvXU1KKKKQBRUU1ylvJCjrKTM/lr5cTOAcE/MVBCjjq2BnAzkipaACiiigAooooA5vwH/yLt1/2GtV/9OFxXSVzfgP/AJF26/7DWq/+nC4rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5ux/5Knrv/AGBdN/8AR99UHxG0HV/E3hFtK0JbIzyXEMjNeTvEqrHIsnG1HJJKgY465zxgz2P/ACVPXf8AsC6b/wCj76t+5a4S3Y2cUcs3G1JZDGp55ywViOPY0AcBe+Cdc13xH4jl1iPTrbTtc0iPTyba7eWWJk3ndtaJVIzIe/RR64ER+Ghu/COq6W2g+GNEvruxktFvdJgwZs4wzfu0KDIBKAv9eK9Jql/a9mde/sdZN16Lc3LRj+BNwUE+mSTj6Gn5L+t3/mG2v9dF/kcWPCHiW98VDWdUXQTBJo66Zc6cwlnSUeYWb5yF4I9UPXGO5n8NeCdR0mdo5pILbSftq3MWlxXclzHbBEIVUd1UgF9r7QAq7QBnNd1VLVtXs9EsfteoSiOMyJEvqzuwVVHuSRRft/Wt/wAxW/r5W/I5bWvB1/qHjCz1jTorLTZ4rlHm1O3uZEnmgXH7l4guyXcNy5ZvlBBArGu/h74lk0u50mxutJgth4gGsW1zKZZHYGbzSjxgKBhuMhzkf3etelK1x9sdWiiFsEBSQSkuXycgrtwBjHO45yeBjmWiL5bW6f5p/p/VxvW/9d/8/wCrHncvgLWJbTXNCaexOja3qD3txd73FwgdlLxLFt287cB9/GfumqWq+CPFl9D47ggg0VY/EqpHbM1/LmFVjEWXHkdSo3YB68Z716HrepNo+hXupJaSXhtYWl8iJlVnCjJwWIHT3pvh/Vf7d8N6bqwh8gX1rHceVu3bN6hsZwM4z1xSW1u2n+X5Bs799f8AP8ziJ/h7Pca5Hquo+HvDOsyXVrBDdwaj+8+zPGCu6GQwsWBGPlKryOopNY8Aa1IfE9roraVHZ+INMitS8heM28kcZjwsaqRsKkfxDbjoa9IooeoLS1jzu88Caxc3Wk3CDTLbU7MwJJrVnNNBMYYwuYzDgiUMQ4w74AIOCeK7LStSuL+e+juLaKJbacxxywTGVJV9clVww7gZAPG4840qKd2xWS2CiiikMKKKKAOb8Uf8jF4M/wCw1J/6b7yukrm/FH/IxeDP+w1J/wCm+8rpKACiiigArm77/kqehf8AYF1L/wBH2NdJXN33/JU9C/7Aupf+j7GgDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/Hn/Iu2v/AGGtK/8AThb10lc348/5F21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/AGBbP/0QlcrfeKdcg8a2X2fVXubGbXRpslvDbIbWOMoTgyMokMwYc7WZR0Izmuq+HH/JLPCn/YFs/wD0QlEngDw3JdvcmxlWRrwX/wAl5MqpcA58xVDgKTnnaBu75oXxJvb/AIK/S4PWLXX/AID/AFseeaRf6voHg+/13TNTcR2/ie5il04wxtHcpJeeWRuK7w3zZBVgPUGneO9S1PxL8P8AxNqI1JrezsdUFiunLChVljuI1LOxG/eTkjDAAEZB616TF4M0GHVjqMVjtmMpn8vz5PJEpOTKId3lh8879u73qtqfw88L6xdXk+oaZ5pvipuohcSpFOykFWeJWCMwwPmIzjjOKa0t5f8AA/yf3jdm35v/AD/zX3HL6p4l8QXWl+Ldb0rVDYr4ZuJIobE28bRXSxRI7eaWUv8ANkgFGXHHWqN54q8VXH/CZXMesCyj0nSrbUbOCKyjyheJ5DG5fduB27SeD6bec95L4I8PS3Cy/wBn+WAqo0EM8kUMoUAKJIlYJJgAAblOABVa7+HPhu+utVubm3vWk1dBHfY1S6UTIDwpUSAADoAAAASOhIpdLLt+Pf5/gEbXV/6/4bbzMOy13xA/iy0sRqyyJq/h99RjWa1QpZzKYwNgXazL8/KsxPHBFZGjeK/FWsWvw/Z9ZigXXkuRemOyQyMyI7AqTlVxgYG3qOcjIrtP+Fd+HftVtciLUFntbQ2UMi6vdhkhIwUBEv0568D0GIbP4YeFtPbTms7W+i/sssbIDVrsrBu+9tBlxg5wR3HFVdX/AK7v9GvuJV7a7/8AAX6o5iw8Ua9qWhWdo+tyx3g1O+s3mtLWN7y6WB2VCiGMxL/DvZgqjtgkVDpus3viC8+FuqaqVa8uHvDMyoFywgcZwOB07cV19n8NPC1h5JtbK6RoZ3uEc6lcswd/9Z8xkJIbHzKThu4NOg+G/hi2n0yW3tLuJtKdnsgmpXIWAsSWwvmYwckEEYI46cUk9df60B9fn+JV8Y6nrdp4v8K6fpepJZ2eqXM0FyFtleX5YXcFWYkD7vTaefUcHBXxJ4gMl1oU2uMJ7PWWsvt0FrG15dxeQJQI4/LMW8FgGYqFCgng1q+P9F1DW/FHhX7Po17e2FldyTXlxa3ccBiVomjBU+aj7gWDZXnA4OeK3D4G8PG1s4BYugspmuIZI7mVJRI3DM0gYO5b+LcTu75oVrf13X/BKe+n9b/8A4nRvGHie8s/A01zfRqNS1G6sb+N7VPMl8sTbSSrFVP7sZCjk9CBxVe18V+K4tLTVb/W0na38Vf2RJbQ2ccUU0JmEXOdzgjO4EMPQ7q7Q/DXwv8A6HstLuIWNw9zarFqdzGsMjklmULIAM5P4EjoaiPwt8KGwNkbW/Nubv7cU/te75nznzM+bndnnPrz1pprmu/61T/K/wB5L2t/Wz/zX3HX0UgG1QBnAGOTmlqRhRRRQBzfgP8A5F26/wCw1qv/AKcLiukrm/Af/Iu3X/Ya1X/04XFdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/JU9d/7Aum/+j76uf8AjdcWVr8PPNvrwWrrfWxhzcmLefNXcMAjeNm8kHIwM44zXQWP/JU9d/7Aum/+j76uko6oD5+8T33hS71D4nXI1Wyu2XTLeazeS/8AN2z7Xw0WWOGDsoG37pYAYzitaUWl349m1bSreyutYvfCCT6XdLEjtNdAupdGxywBUEg8DAJxXtdFHS39bNfr+A76/wBd0/0/E8S0HRbTUbS6vdP8YaZbNc6c1pfW+naZJC6TMVxJdgzu3mBsqSwVjlufSnrZ0zUvANzBd6JoQt9I1mwV73S0D2EsfmqHZARiPClg65IGcEmveaKq+t/T8Hcm2n9drHgfibUPDNnrPxAtLTVoLOJvDlubeBL9odkq+ZtjjXcCuP3f7tcD5gMfNza07WPD2keKNNOk3sRN34Oke7XT51e4uZECFOcktKFEm3OTgHsK9yoqf6/CS/X8Cr6/1/d/+R/E8D0XUdE0m41iW3vdKsrC+8J+aBbzjZLKGZSzyHAlm+YBmCg5ODXqvw1u7e9+GHhyWznjnjXToIy0bhgGVArLkdwQQR2Irp6Kq+jXf/Nv9fwJtr/XZL9AooPAPGfas/Q9Yj13SxexW09r+9kiaG42b0aN2RgdjMvVT0JqRmhRRRQAUUUUAFFFFAHN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95XSUAFFFFABXN33/ACVPQv8AsC6l/wCj7Gukrm77/kqehf8AYF1L/wBH2NAHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+PP+Rdtf8AsNaV/wCnC3rpK5vx5/yLtr/2GtK/9OFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/AJF26/7DWq/+nC4rpK5vwH/yLt1/2GtV/wDThcV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/wDJU9d/7Aum/wDo++p3jHxVJ4Ts7GdNLm1AXl7DZ/u5UjERkcKCSxz1PYH3x1ptj/yVPXf+wLpv/o++rnvjPqNpY+GNJW51C3sZH1qyaN5nUYCzKWbBIyFHJ9qF8UV5r8x9H6P8i3d/EuLRZNTtPEtlb6bf2LwBF+3AwTJMxWN/NZU2gFW3ZXjacZ4zlQ/GaO4iCWmjx6hcJqkOmzPp2pRz2ymXGx1lwC4IJ4CDBUg44NbUngKTUxdalqOtCXWrh7eWC/tLby4rfySWjCRl2yuWbdlju3HkcYXX/CHiHxBY6ZHdeIrBLiyvor1nTSn8uRom3IAnn5X/AGvmOeMbe7Vrq/dfdpf9f0E/L+nZ/wDAt+Jz3iKbWtf8aaDpXiXw5pf9mzWF1Pc6fdakZE+Ro1Mh2wkFlBynruPKEVraX46Flp+gSf2I8PhzVGjtNNvBemaYEjEXmoy/KGxgNvc8jdjJxqat4U1TUvG9jraatZR2lrbSWrWUmns7SRylDJ+8EwwTsGDt47hqrWHgCW1t9M0y51SO50XR5kn0+1+yFZVZAfLEku8hwpORhVPAyTzkVrJP+tX+lrfiD/r7v89/wKenfEfWNUsbu8tfBd2YLW6msnUXaNIsyOqAFVB+XLNlgTtCE8jmsrXfiRrV14Xu20eysIb+y1u30y6MeomWI73j/wBXIsYJzvCnKgr83BIxWrB8N9RHhDVtFu/EFvI+oakdR86LTiiBmkEjRvGZW3xkjBXI4JBJouPhndXNpq8Ta3Ajahf2uoxmPT9qwSwCPjb5nzIfLHGQR6nrRG2l/L9L/qD628/1t+hZXxrbWGv+If7c0RNOn0bS4bq6vI5ElM8Z3nahADFQVbG7aSSflGeSXx/f6fe29trPh1on1C1ludNFpeLKZzGu8xPuVBG+3nqy8H5vVJvh7c6j4g1u71vV4byw1nTk0+e1SyMUgRd2GEnmEZy7H7np0xzM/grU7ryZdS1u1ubnT7eWDTZP7PKrD5ihDJKvm/vH2jHylByePRPbTe3+f/AH1/ry/wCCQ+HviJPrV34dW70UWNt4isnubST7X5jqyKGZGUIAAVOQwY9OQK2/COn6npejzW+sRWkczXtxOn2W4aVSkkrSDJZEII3kYwemc84HN6R8OdX0u48Is3iGzlh8MwPAqDS2VrhXXact552naB2POT0OB2GuTajBp4fRhG115igRywNIJB3X5WXZn++cgeh6VcrX0/rXQlXtZ/1oaNFFFQMKKKKACiiigDm/FH/IxeDP+w1J/wCm+8rpK5vxR/yMXgz/ALDUn/pvvK6SgAooooAK5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6PsaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/9hrSv/Thb10lc348/wCRdtf+w1pX/pwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/hx/wAks8Kf9gWz/wDRCV0lc38OP+SWeFP+wLZ/+iErpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vwH/yLt1/2GtV/wDThcV0lc34D/5F26/7DWq/+nC4rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5ux/5Knrv/YF03/0ffV0lc3Y/8lT13/sC6b/6Pvqj+Ik0Vv4Nmlub+GygW4tzK08ojSVPNXdEXPChxlcnjnnjNA1qdRRXjum32hf2D4o1jTLj7NpQhjhh0rStWjcWSnAdykEkkEQY8lgCQoYnqRVnw5b2n9peLtI0q+0/TLa9sLWe1OkwkW0O9ZFMigHa2SBl12546EZp23JueoajqFtpVhLeX0oihjA3MT3JwAPckgD61ZrxnUDaah8Ntc03UNI0Oa30mS2b7XpKiSykAl+cqmMRuoD71GcBuSau2tp4U1H4yT6PbyWkti2hxeXYx3JEcciy7lEcYbCfIqsAoGRhu+aLe9b+trg9It9v80v1PWaqp/aH9ry+Z9m/s7yV8rbu87zctuz22424xznNeS6p9mu9M1+HUfKj8f295O2kknbdFd+bfyD94xbdoIX5fvbu9V/FmqaRaeJPG1vfa5Fb3cnhuFnQaoyFbkGT5UG/Kn/V/IuM5GQd3M3sr+X6XLUbvl87fil/XdHtlVdP1G11S0+02Molh8x4w69CUYq2PxU15fpGoeHI/HnhCOwvtOL6poMsd0EnRmu+IhGH5y/SQLnPRgOhrFVNO0P4aJ9ht20+wi1m4j8QNpdjE00cIkmCeYjRsrKMx5VlOEII4xVyXL/XnYiLul/XS57pVW51G1s7u0tp5Qs15IY4Ezy5Clj+QU15jpWm6JqHw0nHhTxG82lzXYmjk1ywWOycKvzReUI4lEJC5OAF3evIqGZ9I1248G6lr2haXHFHqVxb+Yqrc20n7lzGYXZRuRmClRgfMABnAoS1sJu0bnqlv9v/ALQu/tX2b7H8n2Xy93mdPm35469MdqtV4R4u1XQIB8SLYa7Ek2+1eOM6o28yAfOg+fOAxIKfdHTFdLHrPh7TviTqCaPe27LdeHftMsOnTo011IpLBwAcvJ5ZyDySMHpUX0v/AFtcrrb+t0v1PTblp1tJWtEjknCExpK5RWbHAJAJAz3wfpWN4K1y68SeD7HVr+GGG4uA5eOEkouHZcAnk9Ov6DpXn3g680jTfGlne2dzpltp99oMssj2jZErxyR7pJ5RhZJAGO5toK/Nk88dV8Ir60vvhnpxsrqG4EbSo5ikD7W8xjg46HBBx7irtb+vNr9Cb3f9dkztaKKKko5vxR/yMXgz/sNSf+m+8rpK5vxR/wAjF4M/7DUn/pvvK6SgAooooAK5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6PsaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8AIu2v/Ya0r/04W9dJXN+PP+Rdtf8AsNaV/wCnC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/Af/Iu3X/Ya1X/04XFdJXN+A/8AkXbr/sNar/6cLiukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/kqeu/8AYF03/wBH31XfEuiPr+kGySeGMFwzR3NqtxDMB/BJGSNy5wcBlPHWqVj/AMlT13/sC6b/AOj76qPxPiQ+GbO4Zpla31WyZfKkdc5uEUgqp+cYY8EH6ZxRa7S7tfmNF7wx4L0/w7IbqPTtFt79ozE82k6WtkjISDgqGYnoOrHpwBXSVzsfjXTEOsDU0n0ptHVZLkXuwDymzskBVmG07T1IIxyBWXp/xY8N6ja6pNA8rtpcXnzRWzRXjNFnG9fs7yDGeoJBA5IA5ob7iS7HbUVzMHji1uL2ytU0vUg+oWZu7EtHGBcgBSyD5/lYbh9/aOeCaltfGmnXehRakkVyrzXLWaWTKvnm4VirRYDbdwKtzu24BOcc07Nf18gWqv8A13Ohorkbv4kaVp2janfapZalZTaVs+12L24eeMP9xv3bMhU4PzBtvByQQamufHljZ6jZ2N1pmrRXF9ctbWoa0+WZgm/IfO3BHTJB4PHBwgOoorzaz1sWHjzXdXj0rWJfP0Wzu5LBjmaL55g3yySBEICjKhhnBwCa6e68aWUdjYXGm2d7qz6ham9t4LNUDtCApL/vHReN68ZzzwDTasv6/roxta2/rp/mdFRXPP4zsZNL0u70y1u9Tk1aHz7O1tlRZZIwAWb94yKoAYZyw64GTVeT4i+HovD8msS3EkFuk5th9rjNrvmGcxq02xCQVIzu25B5pPTcW51NVNV1GHSNJudQuUmkhtozI6wRNI5A9FXkmuYtPGMfjLw5Jd+D5ZHnt7tYbiNJIJBHwCwd1ZkZNpGTGxPocg1U8MDUX+G80cFpc3UD6bGunQq0Y8xDFgBS7KwPTPmEc9OKUrqMmt0ONm1c7awvI9Q062vYQyx3ESyoHGCAwBGffmp6y/DUdxD4V0yG9tZLS4itY45IJGRmRlUAjKMynp2JrUq5JKTSIg24pvcKKKKko5vxR/yMXgz/ALDUn/pvvK6Sub8Uf8jF4M/7DUn/AKb7yukoAKKKKACubvv+Sp6F/wBgXUv/AEfY10lc3ff8lT0L/sC6l/6PsaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/8AYa0r/wBOFvXSVzfjz/kXbX/sNaV/6cLegDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5v4cf8ks8Kf8AYFs//RCV0lc38OP+SWeFP+wLZ/8AohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8B/8AIu3X/Ya1X/04XFdJXN+A/wDkXbr/ALDWq/8ApwuK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsf8Akqeu/wDYF03/ANH31N8d6RrGt6Hb2egxWLyre29xIb25eFQsUqyYBWN8klcdBjOeelOsf+Sp67/2BdN/9H31b9zM8Fu0kVvJcsuMRRFQzc9txA9+TRs0wOC1PwXr2ta94jmuGsbC31Szto7W5t7p5ZreaBmdHKGNVI3NnG7+HvnizFpvxCvfCWr2PiKbw7c3lxbtbWq2fnQRkMNpkkdg5zg52qmPfnjuahN5bi+WyMq/aWjMoj77AQCfzIoauuV9RptO5xFp4c8UQ6x4TuZbTSPK0WwktbnbqEpZiyquUHkcgBAeSPvEdsmnp3gfxEmkI1z/AGZbapY61Nq1iYrqSaKTzWctFJmNCo2yFdwDeuOx9JqG7vLextmuLuVYolIBZvUkAD8SQPxpuTvf+t7/AJkpWjyrb/gW/Jnn/ibwPrviDR9euFj02LWdatIbExG8kMFvFGzNuEnlbnYlj/Avb0ydTxFoWv6tqXhW5tbfTVGk3X2q6WS9kGT5TR7UxEdw+fOTt6dOeOtWZzePCbaVY1QMJyV2MSTlQN27IwDyAORgnnEtF7Df9fM4q70TxK/i7X9St7XSntb7TI7K2D30ivuQucuBCQoPmnoTjaOueKeneEPESaF4f0rUxpk9lY6ebK8sxdymJnACrN/qx5vAOY2AA3dTgGu11bU4NF0i61K8WZoLWMySCCJpHwOuFUEmjR9Tg1vRLLVLRXWC9gSeMSABgrKGGQCecH1pbpr0/X/Njb1v/XT/ACR5hqeneJvDnh3wto+iabBquu6bavGTp2oxW00MQVU3KZ42RlJHIK9QuB8uat6doOv6t4JtV0zTP+ET8Q6NqD3MEd7dJexTyOGLmR4+ocStngFT0HAr0HVdB0jXoUi1zSrHUo423Il5bJMFPqAwODVyGCK2gSG3iSKKMbUjjUKqj0AHSndu7e7E+hl+G08RLpQbxfNpsmoMfmXTI3WFB6AuSxPvx9PXXoooYkZer3OqQXmmjS0s5IZLkLeJcMwk8rB5iwMFgcE54wDWpRRSGFFFFAHN+KP+Ri8Gf9hqT/033ldJXN+KP+Ri8Gf9hqT/ANN95XSUAFFFFABXN33/ACVPQv8AsC6l/wCj7Gukrm77/kqehf8AYF1L/wBH2NAHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN+PP+Rdtf8AsNaV/wCnC3rpK5vx5/yLtr/2GtK/9OFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/AJF26/7DWq/+nC4rpK5vwH/yLt1/2GtV/wDThcV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc3Y/wDJU9d/7Aum/wDo++rN+LN1e6f4Fa903UrnT5oby2y1u4XzFaZUZWJGcYYngg8DnHFaVj/yVPXf+wLpv/o++rW1XQ9J162S31zS7PUoEfesV5bpMqtjGQGBAOCefejqgPK/E8+ppqPxIkHiHVgNJ063vLFI7sxLbyFJH4CbcjIHDZyPvZ4wl5K1v8R9S163a5l1KPwjFewRLeShJZyXAXyw21gcD5MEZ5xnmvRP+ED8IYmH/CK6JicBZf8AiXQ/vACCA3y88gHn0FaFvoOkWkttJaaVZQSWcRhtnjt0UwRnqiED5V9hxR0/rs1+q+4d+/8AWqf6P7zzPS7bxjc2R1Kx1zT4LTVNMYRtJrs155tydpSRN8KiEclSE4G4YGRWZ4plh1Twg2mahb6vp1/pet6bHcW0+ryzhd8qAMkwfc4IJILEMDg4U4r1y18N6HZNctZaNp9u12264MVqiecc5y+B8xzzzQnhvQ49Ll0yPRtPWwmYvJaLaoInYnJJTGCc85xVXXMnbt+Dv/wCbaf12seZa7eajY6h47ttN8SamtvY+HYLyyb7SJDAwEv3WYHO7YMscucn5umJ7XVbnQtesjca7ffZ7zwlJf3ct1M9wI5Y/LxMsZOAcM2QoAbHPPNd5c+B/Cl5cS3F34Y0aeacASyS6fEzSAYxuJXJ6Dr6CnQ+DfDFtdRXNv4c0mKeGPyopY7GJWjTBG0ELkDBIwOxNT/X4S/zX3FaX/r+7/k/vPNdJvL+K612ynvb6W0n8K/bdl9fm4d5DvBl2lmEW4Y+RGKjivQvh6c/DXw3j/oF23/otan/AOEK8LG3WA+GtH8lYzEI/sEW0IW3FcbcYLc49ea0tO0yw0ixSy0myt7G1jzsgtoljRcnJwqgAcnNVfRrv/nL/P8AAm2q/rov8vxLNFFZ+n6smoX2o2gtp4JLCYROZdmJMqGDLtY8EHvg+1SM0KKKKACiiigAooooA5vxR/yMXgz/ALDUn/pvvK6Sub8Uf8jF4M/7DUn/AKb7yukoAKKKKACubvv+Sp6F/wBgXUv/AEfY10lc3ff8lT0L/sC6l/6PsaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8i7a/8AYa0r/wBOFvXSVzfjz/kXbX/sNaV/6cLegDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5v4cf8ks8Kf8AYFs//RCV0lc38OP+SWeFP+wLZ/8AohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8B/8AIu3X/Ya1X/04XFdJXN+A/wDkXbr/ALDWq/8ApwuK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsf8Akqeu/wDYF03/ANH31P8AF3iWfwvb6bcRWEd5Fd6hBZS7rgxtF5rhA4Gxt2CemR9aZY/8lT13/sC6b/6PvqseLvDh8UaGtlHd/Y54bmG6gnMXmBJInDrlcjcMjBGR160LdX2uvuvr+AdzgviN4gn1rwf450i8svsUmheQ0c1tfOwnWT5lLAKmPl6qdw574zXWap4vvbW9vLLQNEbWJdLt4p75BceUwVwSEiXa3mSYUnado6fNk1i6z8LtU1ePxEf+EpWObxCsCXIbTVaKMRqB8ihwwORxlyADggn5q3I/Cmq2niA61put20N1d28MOpRyWBeG4MeQHjXzQ0bYJHLOMY4OKa2t/WwPf+vIxfEfxi0nw/fTxSfYjHYvGl7DPqKQ3aF1Vv3duQTJtDjdyvQ4zip7f4japeXGsiz8HXs8Gj3DQT+XdRtM/wC58xCka53bsqMA5G4H1A2IfC+o6frt3eaPrSwWuossl7b3Fp5rNKECeZG4dQjEKuQVZcjgCsuL4f6kbLxZb3PiCP8A4qKXzlktrJomtm2KmMmVt42ooI+XPzc88Glvl+On/Bt+IdTE8R/EnWT4Q8WR2NjY2mr6NFCZHg1EzxoswOCrCNSJFwflKjHBya6K38U+V4zj07XdChs7yDRpL19RS4WZRGHQMiNtVyucE7gvKjg9aoXPwwuL2x1y2n1m2jTWNPgtGW107ykgeIsVZF8w/L833Dz/ALVX38EaldeMY9Y1LWrW6tTpj6bPZjT2QyRudzEOJflO4DHynC8HJ+ah+Xn+T/UFqtf61X/BIYPiJc7tHuL3QWi03XhjTJoroPK7lC6JLGVURlgDjDsPUiodE+JlxqqaDc3OgGystavJrGN2vA8kUqeZjKKuCpEZ53ZB7Ec1btPAl3Bb6XaXOrwXVnoeG0mNrIho3WMojTMJP3u0N0UR571l2Hwy1qx07w9Z/wDCS2LpompSagrf2S4MxcsSp/f8f6x+f930Oa92/lf8P8/+AJ3t5/rr+G34lXTD4n/4Wrcef9q2+TD52fI837P582zdj93t+99395jZ33V2+kWOpW3iPW7m8itVtLySN7Z4rhnkO2MId6lAF6Z4ZutbdU9WkuotKuH091S5C/u2e3acZ90VlLf99D61F7Ip6yv3sXKKhs3nexge8jWK4aNTKinIVscgH61NQ9BBRRRQAUUUUAc34o/5GLwZ/wBhqT/033ldJXN+KP8AkYvBn/Yak/8ATfeV0lABRRRQAVzd9/yVPQv+wLqX/o+xrpK5u+/5KnoX/YF1L/0fY0AdJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc348/wCRdtf+w1pX/pwt66Sub8ef8i7a/wDYa0r/ANOFvQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc38OP+SWeFP+wLZ/+iErpK5v4cf8ks8Kf9gWz/8ARCV0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34D/5F26/7DWq/+nC4rpK5vwH/AMi7df8AYa1X/wBOFxXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzdj/wAlT13/ALAum/8Ao++rpK5ux/5Knrv/AGBdN/8AR99U3jOS+i8Nu2mStFIZ4FkMbYkMRlUSKh/vlSQMc5PHOKAN6ivNIrm+sNM1+/Gs65p+gxxxwaaNQhLzCRiAzYnUTk7iFUu+PmPYA0uiy6vFqXi7RLO+e0ljtbeTT49Q1J7toZJFcHMj5ZclRwCwHUdcUCPRp54rW3ee4cRxRruZm6AVJXkevzrqHw/1bR9Ys9U0y/0ySzeaGXVJJlIaYASJOH3Mpw3DkEYHAwK1ksp5/ihcaDHr2rjTF0SOeGNL5i0Uiz7SQ5yzE7OS5YnLDocU+tv62uHRvt/ml+p6NVVLi7bV5bd7LbZrCrpd+aDvclgybOowADnod3tXml/qV/e+FvEfiCPUr218QaLe3EcFnFdOIlCPiKJoM7H8xdpyyljv+Ujin+IL/WodX8YLHrWoWpi8NxX8EaNHi0lzJuCDbjB8sAk5PJwRxhPRX+f4X/r+r2otu3y/FI9SqOC4iuULwSLIodkJU/xKSCPwIIrgdPkuoPGXhqA6hfTRavokz3iTXTsrugh2uozhG+duUAJzzk81ytlep4W+G9iLLV2022vtYuLa+vry4uLlLWPzZwpx5ytGGZVUsrLyckk5NVKLX9ediE7pP5/hc9sqOW4iheJJZFVpn2Rgn7zYJwPwBP4V5zYQ6tc+CbiDw/4ssfFTG8XYba8lgBi2/NbrciWWQNwW3FywzjIGCKl5JYeI9c8IXF2urafJb6jd208E+oyRvC6QOxUvHJhug+YE5GQT1FJK7t/X9f12Buyv/X9f13t6Xbz3cmoXcU9l5NvFs8i480N5+RlvlHK4PHPWrVeS+Jr7WbS3+IP2fxBqSGxNpLasroDCrrkxrhcBeeo+bgfNW896+heOtTik1S6SxbQft8z3MrTrFIrlTIqkkL8vVVAU46VN9P67XH/X42/U7e5leC1llige4dELLDGVDSEDhQWIGT05IFZnhTX/APhKPDFprAtWtPtIY+Q7hmTDFcEjjPHb9a43wpeXlr46trWa8vGtNQ0U3RW91Bp2mlEiDzBGzMIchzhEbHPQYFbnws/5JrpX/bX/ANGvVWt/Xm1+hKld/wBdkzrqKKKRRzfij/kYvBn/AGGpP/TfeV0lc34o/wCRi8Gf9hqT/wBN95XSUAFFFFABXN33/JU9C/7Aupf+j7Gukrm77/kqehf9gXUv/R9jQB0lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzfjz/AJF21/7DWlf+nC3rpK5vx5/yLtr/ANhrSv8A04W9AHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfw4/5JZ4U/7Atn/6ISukrm/hx/ySzwp/2BbP/wBEJXSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfgP/kXbr/sNar/6cLiukrm/Af8AyLt1/wBhrVf/AE4XFdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN2P/ACVPXf8AsC6b/wCj76n+NvDzeKPDUmlm1s72CV1aa1vHeNJlHO0SJlozkA7gCRg8d6ZY/wDJU9d/7Aum/wDo++qz4p8V2HhGxt7vU4ryWO4uY7ZBa27SkO7BRnHAGT369Bk8Umr6DTtqc94L+F+heGoLox6Baad9thMN3Yw6hPfW8y54LecADxx9wdTya6220LSbP/j00uyg/crB+6t0X92pJVOB90ZOB0GayIPHenyjUo7izvrS7065jtpLOZEMsjygGLZsZgQ2RjJGOc4wahh+ImmSwzxvZ30WqQ3Ys20h0j+0tMU3qow5Qgplt2/bgHJGDVav+v67/iTt/X9dvwN2LQdIg0+ewg0qyjs7ksZ7ZLdBHKW+9uUDBz3z1qODw1oVrqY1K10XTob4KFF1HaIsoAXaBvAzgLx16cVzr/FLSY3sYG0zWftl5dSWa2n2PLxzxqSY2bOzOBxhiCDnOMkTXPxHsLa1luf7I1eWG0iSXUWS3QHTwyh8SozhiwU5IQOQOtLzH5HQy6HpM+rR6pPpdlJqMS7Y7x7dDMg9A5GQPxqne+DPC+o3k13qHhvSLu5uABNNPYRO8nT7zFcnoOvoKig8X2l7qTW2l2l3qEUaxGW7thG0UfmhSmcuGOVYNlVIAzk9qzrfxzo4Gs3FrbapJNa6ilhJbyhlaW4KqFWJZWCopBHJ2KeW75Jbp/W//BDzNiHwh4atru1urfw9pUVxZqEtpkso1eBRkgIQuVHJ4Hqabqcfh7SbJ4dQ0+3S11W6WGZFsTJHPLIdoMoVSPmOBufjoCelYHj7xDqtr4KubjTbW7sZGinSbzIT5kIETHzBKjFI9p53EkHGByRUUt1r2teBraR9JuLu9TUrZzbwosLLHHLHITumdVk4U/OpwxIwMZppXdn5fiw2s/X8DsItD0mDS10yDS7OOwUEC0S3QRAHqNgGO/pQND0kWdtZjTLMW1myvbQC3TZAy/dKLjCkdiOlXh09KKQdDCuPA3hO7uJ57vwvos81y2+eSTT4maVs5yxK8nPPNTweE/DtrfpfW2gaXDdxxiJLiOzjWRUC7QoYDIG3jHTHFa1FAGVD4X8P28Cw2+habFEkckSxpZxqqo/31AA4DY5HQ96saXo2maHaG10XTbTTrcsXMNpAsSFj1OFAGeBzV2igAooooA5vxR/yMXgz/sNSf+m+8rpK5vxR/wAjF4M/7DUn/pvvK6SgAooooAK5u+/5KnoX/YF1L/0fY10lc3ff8lT0L/sC6l/6PsaAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub8ef8AIu2v/Ya0r/04W9dJXN+PP+Rdtf8AsNaV/wCnC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/Af/Iu3X/Ya1X/04XFdJXN+A/8AkXbr/sNar/6cLiukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/kqeu/8AYF03/wBH31QfELQtY8RaHaWehR2LSR39vdSG8uHiG2KRZMDbG+SSuO2M556VPY/8lT13/sC6b/6Pvq6Sjqn2A8u1L4d65rmt+IbvU4NF8i/ubS6tIZJXuUZrcbdkyNEoKupOcE7T2NXn8AXMcGnajoej+HdA1bTrwXSWliuLe4+R42V5FiRuVc4Ow7T/AHq9DrA8XeKD4UsLO6Ony3qXN7DaMUkVBD5jhAzZ5IyRwAT9BzTjpZLy/wAv8geur/pGRruieKdZ1vwxf/ZdIjXS703VzF9ulJAMbRlUbyfn++WyQnQDHem3nhLWba98RR6K1jJZ+JGL3El3K6yWjmIREoioRKMKDgsmD3NdZd3xsFubm+8iDTreDzWuGmO4EZLZXbgAAA53HOTwMclreyX9vY3dnEhtLqISs0khV0BUFcKAQevPIx70t01/Wv8AwwXs0/60/wCHOIvvh5crd6R/YcVnYyab9nhj1eO6kjuvs0QT928artm3YcYZgACDgmls/BusyXHilNd0rQb+w1u/W6W2kupHBVY1QK2YRtOUVtwzjJ44BrvLy6isbKa6uN/lQoZH8uNnbAGThVBJPsATWFoHjHT/ABLdXllAHWWGSRBs3MGjXaN5cABCd33SQ3B9Kd22111/T/Jf1cNIpf13G+EfDdzpHheXStclS8jllkItpJnukhhbpD5kg3SKBnlgOuMYrpFUIoVQFUDAAHAFYXgppG8JWolmmnZJJoxJPK0rkLK6jLsSzcADJJNb1D3FHYzYtSuH8RT6e1tEbeOESLcRzFmDZHyum0BSc5GGbIByBxnSoopDCiiigAooooAKKKKAOb8Uf8jF4M/7DUn/AKb7yukrm/FH/IxeDP8AsNSf+m+8rpKACiiigArm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xoA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vx5/yLtr/2GtK/9OFvXSVzfjz/AJF21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/Af/Iu3X/Ya1X/ANOFxXSVzfgP/kXbr/sNar/6cLiukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/kqeu/9gXTf/R99VD4mTNb6TpclyHOjDUov7X2AkfZsNnfj/lnu2bu2M54zV+x/5Knrv/YF03/0ffVtalqVppNhJe6hL5NvHje+0tjJAHABPUijsM8w1Gy8Paeujf2TdQ3Hgi51KafUgJVewhBgYIgx8gh3jJXlQx5xnFc/rlzY6P4a1IQ39vB4al8Tae+jbpgIjGrxPMYcnHlA7jx8owccV7zRTTs0/T8Gn+hL1Vv66/5niPiSTRtS8WfEewtrm31GW48NxypbGf7QTKqyn5FJOCP3ZwoGMg45zUmj3nhmw8dfDuPSbyztVm0mdXghmCRs7Im1hHnbuZjJ8wGWORk449qopLT+vX/P8By1/r0/y/E8p8HJZL4km8Osum6sl1ZzSvq+mSPDdKjlfluwpysjKVw+4E7TgCuz8O+CtO8O3V3cQZeS4lkIAyirG5B2FQdrkbfvsC3J55NbOo6naaTaC61CXyYTIkW7aW+Z2CqMAE8swFWqfp6f1/X5g9fzMu1h0Hw0ltpljHpukLdSMLe0hWOATPjLbEGNxxycDNalVruxjvmg89nKQyCURggKzKcqT34IB69arz6/pVtr1tok19Eup3SNJDa5y7IActgdBweTSA0aKKKACiiigAooqtNqFrb39tZTTBbm6DmGMg5cIAW/LIoAs0Vh3esX9v4407SRBb/YLy0nmM29jKJIyny7cYC4cc5J9h33KOlwOb8Uf8jF4M/7DUn/AKb7yukrm/FH/IxeDP8AsNSf+m+8rpKACiiigArm77/kqehf9gXUv/R9jXSVzd9/yVPQv+wLqX/o+xoA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vx5/yLtr/2GtK/9OFvXSVzfjz/AJF21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/Af/Iu3X/Ya1X/ANOFxXSVzfgP/kXbr/sNar/6cLiukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/kqeu/9gXTf/R99TvHWvah4a8KzappVta3EkMkYdbmRlCozBSQFB3EEjjI7802x/wCSp67/ANgXTf8A0ffVb8U+HI/FehPpVxf3djDI6tI9p5e9gpyB86MMZAPAzx160AYd74l8Qv4m8QaRYRaZbDTbCG9t7iYST+YH35DICmP9WRwxxweegpHXdc17WPA97pl5a2Npqlm93NazWrTc+WpI3CRezkDjg8kHoNf/AIQXOrajqR8SawbjUbJLKU7bXARc7So8jhss55yPmPHAxJYeBbSwsdCt49T1JzoatHbTM8Yd4mXaY32oARgAZADfKOc5y1b8v1v+gnr/AF6f8EydP8YeKNY1i3uNK8OST6DLcNA0pMCkIrlDMJPtO7jGfLMIPUZq3ovi+bV9a1HSpLyzsdSheQRadc2kiTxouQsvL4mUnBygUYJGTjNOs/hrpWn+LJdbsdR1m3SaVp5NLiv2WyeVjkyGIdSTzjOPatdvDcM2t2upXl7d3ZsstawTeXshcqVZgQgckqxHzMR7Z5pdLDe7aOJ0vxN4n0b4XaZrN3Lp+qS3V9FHI7RPAY0ln2E43Nvbc2eqAD6c6upeK/ESaj4rtbOHTLcaFbRXULyiSbz1ZXYqwBTaSExkE7f9rOBbuvh3aXHhePQY9Z1a3s4rpbiMxvCzLtk8xEG+NhtVsHpuOACSOKdN4BWe61q4fxHrG/Wrdba5wtrhUUYG39zwcFhzn7x74IJXadt/+ArfqNWur7f8Era74u1OHRbG/wBMNjZrc6eb3N1C900jbQ3kpFG6vnBzvAYDHTmq0mpnWvFXw91NohCb20uZzGGzs3QK2M9+tatt4DtrZrRl1fVGa3sP7OkLNEPtMHO1XxGMFc8FNpPcmm23gC3tLrw/LBrerBdBh8m2jZoGWRdoU7yYiTlQB8pXpxg5NVpd+v8An/wP61edpWV+3+X/AAf60Vjxxr+o+GtDgvtLtbW4LXkEEouJGXaskiplQoO45YcEjueehzJvEPiQa34g0eOTSxcafaRX9vctayFfLcv+7dPMBLDyz84YDkfLW54q8MR+K9LjsJ9SvbCJJ0nJs/K3OyMGXPmI/AYA8Y6c8cVRk8DiTWtT1T/hIdWWfUrNbOUBbbaiLnaVHk9QWc85HzHjgYj7Ltvr+St+Jqraf11/yMu/8bapL4X0vVtN+w2IvdM+3kXUL3TO21W8lIo3Vzwc7wGAx05p9/4/a00/w5f3jQaTY6parcT3l1bvNBExVSIi6sojJ3HDtxxjBJ4t6b8OrTTI7NIdZ1Zxa2P9nHe8P76352o2Ixjbnhl2se5NaEHhNLTw3a6LaavqUNvbwJb+Zuid5I1GMNvjK8jgkAH6Hmrla7t30/H/AIH/AAdb5pPS/b/L/g/8Dpman40bTvFFnp15d2Wn21xbo0NxcwOYb2VsjZHOGCIRgcEEsDwBjmLWvBd3f69NLA9uLe+MjTN5A8tCERV8yPdmYsVOTleAB2yde88G2N3okOirc3cGkxxLA9jGUKSxKu0ISylgOByrKcjrW+AFUBRgAYApadB6mJe6HfXPi/S9Xiv7aK2sYJYXtmtGZ5fM25Ik8wBfuLgbT39eNyiikM5vxR/yMXgz/sNSf+m+8rpK5vxR/wAjF4M/7DUn/pvvK6SgAooooAK43xHpNtrPxJ0C3vJLyNF0nUXBs72a1fPnWQ5eJlYjnoTjoccCuyrm77/kqehf9gXUv/R9jQBXvvCPh7TbGa8v9T123toVLySyeJdQCqPU/v6xlj8GyW00kd/4sMkVu9ybVtU1eO4aNcAssTSByMsMEDB7V0fjy00q+8GXlpr9xLa2M7RRtcQuEaFjIoRwTwNrFTk8cVydpe6/pPiQaD4sls9aaXSrqTT9YtlMcwiUJvWeMfKMnbhhwSKlvR/P8rlJao2tB8OeH/EXh+x1iwuvEi219Cs8Ql8RX4YKwyMgTnn8atW3gnTJ42aV/EtsVdlCy+JL0lgDgMNtwRg9RnnB5APFcN8JLtdX0/RbHVZ9Q0y8sNHhbT7WK7kSK7hKDNxtDbJCGJXaVO3AznIxVsdR1ufQfC2/xNqrNL4suNPuHEy7riISS4DHbngRgYXAwTx0xtKNp8q7/rYzT927/rRs9J/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+s/4d3U5uPFGmy3dxdQaZrLwWzXU7zSJGY432l3JZgCzYyTxxXK+INWvU8XC/03Vr+RYfEdrYSE3bQwRRtsV4FtwxWU/MSXZVI3cE7ahK7S72/G3+f9aFPRN9r/AIX/AMjuv+ED0j/n88Qf+FHqH/x+sbxRpXhrwjob6rqc/imS3V1jIttd1GRsscDP7/CjPckDpzzXIXF9q1lpGv6m3iHVbi50zxbFa27S3RVPKZ4VZGRNqMpDngjA6jByTF43vRrfgTxdqWq6rcwXem6uLRbP7UY4oYVnjCBos7W3L8+5gTzwQBQtUn6f+2//ACQPS6+Xz1/yPTB4E0gjP2zxB/4Ueof/AB+l/wCED0j/AJ/PEH/hR6h/8froLaeK6tYp7aVJoZUDxyRsGV1IyCCOCD61JSEtVc5v/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+ukooGc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/XSUUAc3/wAIHpH/AD+eIP8Awo9Q/wDj9c/408FaXbaDbPHda4SdW01CJNfvnGGvoFPDTEZwTg9QcEEEA16JXN+PP+Rdtf8AsNaV/wCnC3oAP+ED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH66SigDm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+ukooA5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrpKKAOb/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH66SigDm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+ukooA5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrpKKAOb/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH66SigDm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+ukooA5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrpKKAPO/APgrS7r4beGriW61xXm0m1dhFr99GgJhUnaizBVHoAAB0AroP+ED0j/n88Qf+FHqH/x+j4cf8ks8Kf8AYFs//RCV0lAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P10lFAHnfgvwVpdzoNy8l1rgI1bUkAj1++QYW+nUcLMBnAGT1JySSSTXQf8IHpH/P54g/8ACj1D/wCP0eA/+Rduv+w1qv8A6cLiukoA5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrpKKAOb/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH66SigDm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+ukooA5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrpKKAOb/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH66SigDm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+ukooA5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrpKKAOb/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH66SigDzuz8FaW3xJ1m3N1rmyPSbBwRr98HJaa8By/nbiPlGATgckAbjm34h0fwt4W0z+0Na1DxPFahgjSQ6zqs+0npuEcjFR2yeMkDvWrY/8lT13/sC6b/6PvqpfFlmX4Wa0U27vLTbvOBnzFxk0gKWj2Hg/Xb6aysNU8SreQKHktLvWtVtplU9G8uWRWK/7QGK2v8AhA9I/wCfzxB/4Ueof/H65fW/DniO+vL3xXrF5a6LPp2jTwWaaRcGdwTh2dpJIlH8GAu04yTnNZGk299ZXnw31eXxDrdw2tIiXsdzqMjQOfsbsP3eduSwB+oz1zm0r/13vb8hefr+CV/zO/8A+ED0j/n88Qf+FHqH/wAfqE+CtKW6MTSeJBEI95uD4lvtmc/d/wCPjdnv0x715jZ6rd3N3a2On+LdSaJPGkunyQpqHnMbYqSqs7bpMfuyB82OW6nkb2o2VzZ+JPEnh2413V9Q0+Pwr58aXV4d6Pudc7k2sSQgySSTk84OKzbtHm/r4eYu3vOP9fFynYWfg7Qb+yhu7PUNelt50EkUi+I9QwykZBH770qb/hA9I/5/PEH/AIUeof8Ax+vPvBkEenal4FgttU1EWeo+HpjdwyatO8fmLFCw2q0hEZAZiNuMDpim+GNT1XVfA+nXGm6hPr6afqF99ss01t4rqWNJj5ZEu7LbVK/IzAMHXJ6VrOPK2u3+bREXzJP+trnof/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/V/wAMalbav4V03ULCS4ltri2R43uv9aRj+P8A2vWuQ8TWl9qPxa0zSV8QatZWF7pFzI8FlcCII6PGFdSBnPzZ5J6Y6Egza0uX1/BN/oPpc6D/AIQPSP8An88Qf+FHqH/x+s3xB4f8PeG9Bu9X1C58TvbWkZkkFvr2pSvgd9om/M9AOSQK5TStVvv+E10C6tNav7m11O8v4Jbi6uyI51RHKBbXcyIqFAN42sduSPmpl7fXdj4O8R6H4iF9/az+H7u6W6/tFrq1v02gNKgY5iOSuEwqjccZqZXUbrtf8/8AIqCTmk+6/Ox3Fh4P0TUNOtr2G68RLHcxLKgfxHfggMARn9/15qx/wgekf8/niD/wo9Q/+P1y/hSS40zxxoGnx6heT2+oeGRcTQ3FyzoJIzEqsiH5U4YghQAfTNemVpONnp5/g2v0MoNuKv5fikzm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+ukoqCzm/+ED0j/n88Qf8AhR6h/wDH6P8AhA9I/wCfzxB/4Ueof/H66SigDhNT8M2OjeLfB9xZz6pI7atKhF5q11dJj7BdnhJZGUHjqBnqM8mu7rm/FH/IxeDP+w1J/wCm+8rpKACiiigArm77/kqehf8AYF1L/wBH2NdJXN33/JU9C/7Aupf+j7GgDopIo5k2TRrIuQdrLkZByD+dZcPhXw9b293b2+g6ZFDfZ+1xpZxqtxnrvAGG/HNTa5rNvoGlPfXaSSKHSJIogN8juwVFGSBksQMkgepFZdz4zjsdQ0mzv9G1S1fVLo2kbSLEVik8vfhiJDkEbhldwypGemRK4balmLwX4WhNuYfDWjxm13eRssIh5Weu35flznnFRJ4A8Gx+X5fhLQ08t96bdNhG1uOR8vB4HPsK43xN40n1K50qTSm1fTH0/wATw6ZfWRMQ+05XfjKM2Vxtx8wByciuni+IWmmG6W5sr+01G1uUtW0uaNDcPK4zGE2uUYMASGDYABJIwcC1V/66P9UDVnZ/1uv0ZtaZ4e0bRZp5dG0iw0+S5IM72lskRlPJyxUDPU9fU0y48L6BeXM9xd6Hps89wVM0stpGzSlTlSxIycEcZ6VhwfEewlv7Cyl0rVLee71B9NdJo4h9lnVPM2yYkOQV5DJuHvWVr/xPlt9CvJ9I0LUDd2esw6VPHMYAY2Zk+YfvCGBDgLz1POACadm7f12/zQev9b/5M6X/AIQDwd5DQf8ACJaH5TOHaP8As2HaWAIDEbeoBPPuauT+F9AurwXdzoemzXIjWITSWkbOEUgqu4jOAQCB2xWNd/EOxsb8W11peposc0FtdzhImjs5pguyN8SZJ+ZQSgdRnrUE3xR0iJtQb+z9WNvpl8lje3DWojSBn2gOQ7KxTLDkAnnOMEGjV/16f5r7w2/r+ux2gAAAAwB0AormdV8eabpF4yXNteNZxXKWlzqMaKYLaV9u1Xywb+JRlVIGeSKhvPiJpVjM8ktrfHS4rr7HNqyIhtoZt20q3zb8BuCwQqD360lr/X9d196DY6yiuNvviVY2GmeIL2bSNUZfD9wIbyNFhLYKhhIv73BXawPUNz061q2/iqG81eexs9OvrhLZ44p7qNY/LikcKwUgvv4V1YkKVAzzkYppNhsbtFFFIAooooAK5vx5/wAi7a/9hrSv/Thb10lc348/5F21/wCw1pX/AKcLegDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5v4cf8ks8Kf9gWz/APRCV0lc38OP+SWeFP8AsC2f/ohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8B/8i7df9hrVf/ThcV0lc34D/wCRduv+w1qv/pwuK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsf+Sp67/wBgXTf/AEffVraroek69bJb65pdnqUCPvWK8t0mVWxjIDAgHBPPvWTY/wDJU9d/7Aum/wDo++rpKAKMmiaVNow0iXTLN9MCCMWTW6mEKOi7MbcDA4xULeGdBfR4tJfRNObTYW3x2ZtIzCjZzkJjaDkk5x3rUooAyLnwj4bvJInvPD+lXDwyNJG0tlGxRyclgSvBJAJNSf8ACN6H/bD6v/Yun/2lICHvfsqecwI2kF8bjxx16cVp0UAZbeGNBeztbR9E01razk8y2hNpGUgf+8i4wp9xTrnw3od7Z/ZLzRtPuLbJPkS2qMnJBPykY5IB+oFaVFAGZ/YNoPEEOqpFBHLBbm3QxQhXKZ+6z9So7LwASTzxh8vh/Rp9aj1ibSLGTU4hiO9e2QzIMEYD43Dgnv3rQooAyl8LeH1nMy6FpglM5uDILOPcZSMeZnH3sEjd1pr+EvDkkN1C/h/S2ivCpuUNlGVn2/d3jHzYwMZ6Vr0UAY9r4R8N2N9Be2Xh7Sre6tl2QTw2UaSRLgjCsFyBgkYHrWxRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFc3ff8lT0L/sC6l/6Psa6Subvv8Akqehf9gXUv8A0fY0AaevacNW0eWxeys76KYhZbe9z5ciZ5BwDg+hwcGuFh8A+ILXR9Oa3uLSS603WRqNpp9xezSwwQ+WUMAuGQuR8zMCU4JxjFd9rGrWehaPdanqUoitbWMySN7DsPUnoB61OJLhrqMJFGbVoyzSGUhw2RgBNuCMZydwxgcHOQ1o7r+ra/p/Vwe2v9dP1POH+HfiJrjUL17/AEx55Nei1u1twkiqWRNhjeTkgEAchDggnBzgWr/wFrGoX0niM3NjB4h+2293DAGd7ZFhRkETPtDHcJHy+0YyPl459DooTaVl5fhb/JA9Xd/1v/mzjvEOh+ItctdFvlh0uHU9K1FLxbQ3UjQuAjoymby92SHyD5fBGOetYV18PPEdxY6+GvtLeXUNbt9Wt4gsiKpiaMlHk56iMDIXg5PfA9OooTs7r+tn+iB6qz/rf/NnmfiPwN4o128vJriXS7xvtlpd2Dz3EyC2ETIzxLGEZVztc+YMsd2CMYxU1TwL4y1HRvFtotvoUcmv6jDdxk6jMRCqBAQf9H5P7of99H057jxP4obw3daNF/Z0t0mqX8dl5yyqqwFuhOeTwDgAduSK2omuGmmE8USRqwELJKWZ1wMlgVG05yMAtwAc84Ar20/rb/Jf1cHvr6/mv8zz+H4dbfEV5eXvh3wxqSajN9qkur2ISXFnIVG5UJhPmqGGRlkIzTpPAGpnQ9Q8KK9k2gX9490928z/AGmNXm814xHs2nnID7xjP3Tjn0OihaWt0/r9BHm3iHwDr1+vjCx0ubTY7LxIkbCe4eTzIHWNY2XYFwQQuQ24YPY1auvBWr3WvaXqUY02y1C3kiN3q1jNLDJcRIFzE0GCsgb5hl3O0EYya63xFq7aB4bv9WWzlvfscDTGCJ1VnCjJ5YgcDJ/DjJ4qXRdR/tfQbDUvK8n7ZbRz+Xu3bNyhsZwM4z1xRFvddLf8D8v8xva3e/6X/Qu0UUUgCiiigArm/Hn/ACLtr/2GtK/9OFvXSVzfjz/kXbX/ALDWlf8Apwt6AOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/hx/ySzwp/2BbP8A9EJXSVzfw4/5JZ4U/wCwLZ/+iErpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vwH/yLt1/2GtV/9OFxXSVzfgP/AJF26/7DWq/+nC4rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5ux/5Knrv/AGBdN/8AR99XSVzdj/yVPXf+wLpv/o++rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/sNSf8ApvvK6Sub8Uf8jF4M/wCw1J/6b7yukoAKKKKACubvv+Sp6F/2BdS/9H2NdJXG+I7+5074k6BLZ6Teaq7aTqKmGzeFXUedZHcfNkRccY4OeRx1wAQ/GWyhvfhJrgnto7jyYRKoeMPsIYfMPTAzz9a5N7rwvbfFL7HpGq2+mwTeFZ41W1mwIDuUgxRA4U7FLgKBuA3c9a9A/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoW/3/imv1Hf+vmn+h5/p0dvd6LrXhrfoNmbVbZG1fTELWNywlJMNxEDhWJB8xdxyHyT2qo+o6bNb+F9euNM0vS7bSfEfkS6jZOGsmiMBXzIpCAFiJ8tT0AZfbNel/8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVVKWt/T9P67EtaW9fyseSiaO3m1+301Lew0JvFDS30l1pkj2Qt2tsAugMYaMyrzhsDgn5Tz6d8OtL/sjw3dRWetWusWkly81o9nAYraFGAIii/ePlAc4wxAzjtVz/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KpX923kl9yS/Qb1d/66/wCZ5HJe6M2n+Fry/Ut4ut/EUR1lVieS7U7pCQ6qC5jA+4MbcfdrT086Tqx8d6XZa/YR/wDE+jmX7fKbqGRREhZJQXyYiyupyQBjHbFek/8ACUav/wBCJ4g/7/6f/wDJVH/CUav/ANCJ4g/7/wCn/wDyVQtP6/w//I/iD1d/66/5nn8WrW2pweH5td0zT9P8KLdXkWoGOXzNOmkCAQyBmAUwt82Nw27gB6Vg6hDplpfaJDc6iItDk8VgaRE98yRPYmIF9q7gGi83AUnIAIAOG59e/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoT1v6fmn+lvTQXRr1/FNfr955t4lsvD+mN4s0PXoIrcWulbfDUM7MQIhA277OTk7w5YNt+bG0dKz2gHiC0sbDWdY0/Q4JtHs49Km1fTZDIkqoVdrdmmj2TB/wDZLEbSMivWf+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqkvPy/C/46jerT7f8AA/yPNdH0rw9qnjjxhbajrLXN3ZWNpOLv7U5mt5ljkEsypvJQqzcoOF3bcc4rq/hpcxQ6lqWixWeju1hFGr6nohxbznc+UdOQkwOSwyxO4EnpW/8A8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVVcVjpKK5v/AISjV/8AoRPEH/f/AE//AOSqP+Eo1f8A6ETxB/3/ANP/APkqpGdJXN+PP+Rdtf8AsNaV/wCnC3o/4SjV/wDoRPEH/f8A0/8A+Sq5/wAaeI9Um0G2WTwXrkAGraaweSaxIJF9AQvy3JOWICjtkjJAyQAeiUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAHSUVzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQB0lFc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUAdJRXN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVAB8OP+SWeFP+wLZ/8AohK6SvO/APiPVIPht4aii8F65cpHpNqqzRTWISQCFQGXdchsHqMgH1AroP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgA8B/8AIu3X/Ya1X/04XFdJXnfgvxHqkOg3Kx+C9cnB1bUmLxzWIAJvpyV+a5BypJU9sg4JGCeg/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqACx/5Knrv/YF03/0ffV0led2fiPVB8SdZlHgvXGdtJsFMImsd6ATXhDH/SduDuIGCT8pyBxnoP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgDpKK5v/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoA6Siub/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqAOkorm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqgA8Uf8AIxeDP+w1J/6b7yukrhNT1m+1Hxb4PivPDWqaUi6tKwmvJLVkY/YLsbR5UztnnPIxweeme7oAKKKKACubvv8Akqehf9gXUv8A0fY10lc3ff8AJU9C/wCwLqX/AKPsaAHeP7i/svAWsX+k6jNp93ZWklzFNDHG+SiFgpEisMHHPGfQisXSPGh0yHSdF1H+2df1y90z+0N6WcSCQYUsqsBHGMFuOeOMnJGd7xtpupa14M1PStFjtXub+3e2Bu52iRA6lS2VRySM9Mc+orlNP8N+NYPEWh6ndWOg40nSJdP2R6pMfOZgmH5t/lGYwMc4DZ5xgpdf66P9bDlsref5r/gm1b/EbT7yTw79k0zUprfxBlba5VYhHE4DFkkzIGDAKxIAPTjJq23jJFMsa6Jqj3S3Mlvb2yeQXuvL++6HzdoQerleeMZ4rm9P8Ba9B8J7TQppdOt9d0u5+1WFzFNJJCJFkLqWJRWAIZkIAPBPrirviP4f/wBpQ6HcR2Wk6vc6Wsiy2mrx5t7nzcGRs7HKPuXcG2nqRjnIp2/r+vkJf1/XnoaNl8QNN1VLP+x7K+v5blJHeGJI1e3EbbH3h3XkN8uF3HPQY5rPbx9dx+OtW0u60PUV07T9Nju3miSOR/m3ncUV9/O3aAoJyDkAYNQa38PzfaFDaadoOhWM8KlrV7OeSzbTpH+80UkUeW7HGE3c5wKnPhTxFZeItQ1O0uLHUGvdFhsZGupHhZ5o9/zHajABt+SecYxg5yE9m/X8n/X9aC7f1uv+D/W9uz8b6ZH4f0OTSbLVNRfVLU3FnZq6yXLRKAWd2lkA43DJLkknjJp6/EbSbvTLK70ez1PU3vpHjtraK0MMkhRdzkeeY1wo75wSMDJ4ri4/D3iGwtvCPhy1n0231/R9OlDS2uomJjF8iAq0ltICrYJKmM4Kg7hjnXsPDuqXGk6Tp2l2tlBpul3E8F/YPqMskVyWwfMEqxgy7WZsoyqC2QcbQaqVnfl/rX+vmJdL/wBaf18i0/xJkvfEHhWHRNIvrnT9ahmuGlHlKwVBgqVdwRtLAtjngBd3Iq/pvjvRZtGlv7GHU5DPqUllFaTqwnmuB1REkb5BweGKhcHOKxNB8A+INGHhBw+lmTQY7u2lRZZNjxykbWX5ByMDKnA5+9xUeleAfEcFv9qvBpceo2euz6xZxxXcjxS+cGDRSMYlK4D8MA3rjsVpf+u6/QfTz/4D/Wxt3XxS0TT9JvLzULTVLaewuUtbuxNr5k8Dv9zdsLLtbIwwYqegOeKst8QdOhbVIrqxv7a602SFDayrGJJ/OO2EphyuGPHzFcH722ue8R+AvEGs6XrFxAmlpq+tXNm88b3cggt4rdgyqriIl2JB5Kr9725tt4S1298X69f6tpeg3Wm6vaW1u1rLdySZERYncDCBzvODzgqODng9f62/4Pf5gdvp9699bs8tjc2LqwVorkLuB2g9VZlI5xkEjINWq5rwP4f1Dw5o9xa6jcBlkuWlt7VbmS5WzjIAESyyAM4yCckDG7AGBXS0MSCiiikMK5vx5/yLtr/2GtK/9OFvXSVzfjz/AJF21/7DWlf+nC3oA6SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/Af/Iu3X/Ya1X/ANOFxXSVzfgP/kXbr/sNar/6cLiukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm7H/kqeu/9gXTf/R99TPHviifwvods2nRRzalqN5FYWSS52CWQ4DNjqAMnHGcYyKfY/wDJU9d/7Aum/wDo++p3jXwovi7Q4rVLr7FeWlzHeWV1s3+TNGcqSvcdQRnoaOqvtdfd1/Aa/r9CJtJ8TWCwzweJJtSY3ERuYLm0gVRFvG8RbFVlO3P3i5wMDnmsaT4vaedMutRsfDfiS+s7N5kuZobFE8gxY37hI6kdemM8HjiuisG8WTkR6vBpNoqEEzWd1JM0wHbY8SiPPHOX7+xrO8CeHdW0bS9YtfEcNh/p+o3F4q2lw8y7ZmyUbdGnTp3z7Ua6/wBdhaaev4a/8As3fjm0sre2uLnTr9beawN+8y+S6wJxhX2yH5iWAG3cD64BIzfF3jnUtE8Mw31r4d1FLia8t7YxzNBmMSuFzkSFWPOBgkAkZIGTVbwT4buIPCmpWlwbXUoTK+n2a3SkxvYxSMqo/XPDOM4weKpP8ONYHhq+sLKW0tEOpWt7YaYbyWe3tlhkVigkZNyh9v3Qm1ewNVo5eWn3X/y/IWtvPX77f5nQ3fxDsbG/FtdaXqaLHNBbXc4SJo7OaYLsjfEmSfmUEoHUZ61B4Ou76Tx141s73ULm8htLu3Fus7DEKvCHKqAAAMt6ZwBknrWP4j8DeKNdvLya4l0u7P2y0u7B57iZBbCJkZ4ljCMq52ufMGWO7BGMY3fC2ha7pvjTxLqmrQ6clpq8sUsItrt5JE8tBGAwaJRyBng8HjnrSVrX9f0/4P8AWrb/AK/Er/EDxUbTQNdsNHGpm/s7Fp5rrTljP2LKlkLFz329FDMAc4HBpbHxrFpPg7SpLq21DVbiPSYLy+a2CyPDGU5lcuylslW4XcxweDUGteEPEB1HxN/YUunS2fiS12TC9lkR7WYReUGXarB1IxkErjGcnpWbF8MbmG50271HS/DfiSaPToLC6j1KAosYi3bZISUlOcNhlOAxAOV6Uo7Pzt+v/AHK118//bf+D/W+4PifpNzNfR6Tp2rap9htoruZrW2AUwyAkOnmMu8YUn5ck9s4OLNx8QNM8lZNJtL7Wl+yR30v9nxo3kwOCVdt7LnO0/Ku5uOlcnZ2er2vxM8S6b4at9JTGj2EDCVmhjt1xMAyRorBgP7ny9vmFa2j+BNS8GzsfC7Wd7Fc6fbWVwt/M8RjMKsolXaj7shuUO3kfepvZ2+X4/8AA/rZdbP+tv8Ag/1vtQeOtO1CaFdEtbzVo5LNb1pbNUxHE+7YSHdWJYowwoYgjnFYPiX4hw6ZoPi6+0Cw1G41DR2SCdbjKRxuwwrqkjD5RkH5QN2QeetQXvwxuIfD2l6Xoi2cd3psCQW2t/aZILq25JdgEUiQFuRGzBeTk1HqHgLxLqkPjmC4OlxJ4hERtJFupHZWiVUHmL5QADBckgnGcYPWm7X08/zX6BHpfyPRtPuZbvT4J7i0ms5JEBaCcoXQ+hKMy/kTVmoLIXIsohfCIXG35xCSUB9ATgn64GfQdKnpPcUdlcKKKKQzm/FH/IxeDP8AsNSf+m+8rpK5vxR/yMXgz/sNSf8ApvvK6SgAooooAK5u+/5KnoX/AGBdS/8AR9jXSVzd9/yVPQv+wLqX/o+xoA6SiiigAooooAKKKKAM/VtA0fXokj1zSbHUo423Il5bJMFPqAwODV2KKOCFYoI1jjQYVEXAUegA6U+igAooooAKKKKACiiigAooooAK5vx5/wAi7a/9hrSv/Thb10lc348/5F21/wCw1pX/AKcLegDpKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5v4cf8ks8Kf9gWz/APRCV0lc38OP+SWeFP8AsC2f/ohK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8B/8i7df9hrVf/ThcV0lc34D/wCRduv+w1qv/pwuK6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAObsf+Sp67/wBgXTf/AEffVv3LXCW7Gzijlm42pLIY1PPOWCsRx7GsCx/5Knrv/YF03/0ffVz/AMbriytfh55t9eC1db62MObkxbz5q7hgEbxs3kg5GBnHGaOqA9ErJ1CXRdX1B/Dep29vfs9v9pltLiJZU2BwFLK2R97px/CfSvFPE994Uu9Q+J1yNVsrtl0y3ms3kv8Azds+18NFljhg7KBt+6WAGM4rWlFpd+PZtW0q3srrWL3wgk+l3SxI7TXQLqXRscsAVBIPAwCcUdn/AFs3+g/R/wBXiv1PaY40ijWOJFREACqowAPQCqmravZ6JY/a9QlEcZkSJfVndgqqPckivH9B0W01G0ur3T/GGmWzXOnNaX1vp2mSQukzFcSXYM7t5gbKksFY5bn0p62dM1LwDcwXeiaELfSNZsFe90tA9hLH5qh2QEYjwpYOuSBnBJqre8l6fnYm+l/62ue6K1x9sdWiiFsEBSQSkuXycgrtwBjHO45yeBjmWvA/E2oeGbPWfiBaWmrQWcTeHLc28CX7Q7JV8zbHGu4Fcfu/3a4HzAY+bmxZajYWXiPT4PBl7Zf2pqHg2XCw3Cs9zdKEMO45yzgB8ZOcA9hU7/15Sf6FW1t/X2f8/wAD268uorGymurjf5UKGR/LjZ2wBk4VQST7AE1gaH4v07xRPfWEPmJJG8sY8ov80a4G/eoHlsd3CkhhjPauI8BaJY6lqf2218RadOlxYNa6npulWUtpMXbHz3Lee7rMCCNxCscnmu48P+B9M0C4vZoh5rXUkvy8qgjcj5GTO1yNv3mBbk88mm42dn2f3/1/Vyb3WncreBNB0mHQrDWI9Ntf7VntwJ9QMKm5mz13ykb2JwMkk5xXW1V07S7DR7FbPSLG2sLVCSsFrCsSKScnCqABzVqhjCiiikAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeV0lc34o/5GLwZ/wBhqT/033ldJQAUUUUAFcl4im1Cx8faJf2Oh6hq8SaZfwyCy8pfLLS2hXc0roozsbAzk4OAQCR1tZfiLWP7B0STUNkL+W6Ltmn8oHc4XAbB+bngY5OBxnNAbmf/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVWH4V+IqzeGb2/wDEu+JNOiWW4lELvPtZ3G5oI0JRQFHzDOcMTjFdHp3jTQNUvDa2d/mQWovAZYZIleH++rOoVgM4OCcHg4oAg/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqmsfG3h/Uppo7W/8A9VAbnfLBJEkkI6yRu6hZEHGWQkDI55qnJ8R/Dy6Bf6vE1/LbWEaSSj+zLhGKvnYVDICynH3h8vckCjYCb/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSq2NN1Eaho9vfmCeASxCQxSwujoccgoyhs/UAn0rIi8f+GpjZj+0WiN75nkie2li5jzvVt6jYw2sdrYJwcA07WdhJ3VxP+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKqz/wmGhnQ4dWF4xtZ5GihAgkMskikqUWLb5hYFW+ULng8VWX4geG3tbe5S9ma3ubtrKOYWU5QTKcFWbZheeMtgcHng4XWww/4SjV/+hE8Qf8Af/T/AP5Ko/4SjV/+hE8Qf9/9P/8AkqsHXvHdsmvaLd6ZrdxHpMX2ubU447Iyq8MPyMdvlmTiRlGVIGAx56joZ/HWgW2lw389xdJHPG0scRsLjzzGpwz+Ts8wIP7xXGCDnFHS4a3sM/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqgl+Imjprx02KPULhUsReyXNvp9xLGsbDKYKRnduAYgjj5ccngTWPjLTBbWYv9Q82W8tDewzR6bPDHLCWAXAbd83zINu7cSR8oyBTs/6+f+TD+v6+8X/hKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KqWbxvoEFhZXZu5ZFvlZraGG0mlnkCnDEQqhk+U9crx3xVrw74l0zxVpv9oaJLPNa7ygkltZYNxHXAkVSQDxkcZBHUUgKH/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVUt3430Cy1L7DNdyvPvaMCC0mmUyKpYxB0Qr5mATszuPYUL430OSwivLea7uYJI2lzb6fcSlFXOd6qhKHKkbWAJIIAzR0uHWxF/wAJRq//AEIniD/v/p//AMlVh+Lda1vUNFt4YfAviAMup6fMf3lk/Ed5DIeEuCeinnGB1YqoJG/pPjvw5rl1ZW+mag0z38BuLUtbSokyD7212UKSMjK53DuKjl+IPhuKaWP7bNIYonm3Q2U8qyIhAcxsqESbSRnYTjvih6bgtdhf+Eo1f/oRPEH/AH/0/wD+SqP+Eo1f/oRPEH/f/T//AJKqG8+IOgjTZpbPUXD/AGeKVZBptxOsQlyI2dEUHGVOQSpHQkZFXdW8XaP4cjVNcvwsyRCSfyLaSTy16eY6oGMaZB+ZjgetOzvYCD/hKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KqSTxz4fh+0CW7mQ21x9mlDWcwKv8vONnKYdTvHyYYHPNTaz4u0TQJhDql4yS7Q7RwwSTNGhON7iNWKJnjc2B70gKv/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVVnU/GOhaRfJaX16VlZ0RvLgkkWIuQE8xlUrHuJAG8jNbdHmBzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVXSUUAc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlV0lFAHN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVdJRQBzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVXSUUAc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlV0lFAHN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVdJRQB5/wCCta1vTPAPh+wn8C+IDLa6ZbQufMskyViUH5XuFYdOjAEdwDxW5/wlGr/9CJ4g/wC/+n//ACVXSUUAc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlV0lFAHN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVdJRQBzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVXSUUAc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlV0lFAHN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVdJRQBzf/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVXSUUAc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlV0lFAHN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVdJRQB5/wCEta1vT9FuIZvAviAs2p6hMP3lknEl5NIOHuAejDnGD1UspBO5/wAJRq//AEIniD/v/p//AMlV0lFAHN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVdJRQBzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVXSUUAc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlV0lFAHN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVdJRQBzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVXSUUAc3/wlGr/9CJ4g/wC/+n//ACVR/wAJRq//AEIniD/v/p//AMlV0lFAHN/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVdJRQBzf/CUav/0IniD/AL/6f/8AJVH/AAlGr/8AQieIP+/+n/8AyVXSUUAef2mta3H4+1W/PgXxB5U+mWUKjzLIcpLdE/Mbjaf9YOASR3ABUtuf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBzf8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVdJRQBxN9qGq6x4o8KiXwprGnQ22pyTS3Ny1s8aD7FcoM+TM5GWdRkgDJxnJAPbUUUAFFFFABRRRQBwXxAtIdJ+H8HhzQtOaUaldR2UVlCw3SIzl5lBdgOY1k5JArO8Q+DtZ8S2d9qJ08WTLaRWNlpBlTf9mEqSTozKSgaQIEABKgKPm5OO21PwtpesazY6pfpdNd6e262aK+niWM85OxHCnIJByDkHByOK2Ka016/1/wfvG/6/r7vuPPL/T/EF1rC+JD4baSO2thp9tobTweaYZHUzu53+WDtUBVDkccnnASPQdffwPbaTNYS+QNUjaO1luI2mgskcSJHI+4qSCoU4LHaerEc+iUUJ2/rzv8An+bF/X4W/r0RhajpurpLcalY6zqMjrEzRaSq2ogdwnC72iEmC3OS4/AcVyNn4BvLK+0HNt9oh0DTZbiMmVf9L1GTgscntg4J4+YY6V6XRS/r8/8AP8h/1/X9dWeZ6LoHiLRr7R5f7G+0m10Z4oy91GFgvHffK8vOcvxygbuMgHNJongzVZ7HwdZa9pwihsJZ9U1LEqEG8JJVSFPI3SyNxkfKMmvTaKrm1/ru3+b/AARNv6+Vv69Weda/4a1u+8cT+I47SadNPks4bOzFwgW5hDFp22lgucuCA+OYgR2qtd+Ftfu/G2uXOo2NzeWmrQwJCsV7ElrGiLzFMeJyN244TKsHOR3r06ipWmn9f11Kvrf+tDz7UdD177D4u+xaawn1ER2tq0EsSkW6oqfICwAwGlb5ivJAGat3Wgai2sTaxFp+ZdL0f7NpFoLhdrTMCW5OAD8sagnHf6121FD1X9drCWn9ej/Q8nbR5YNS0KHS4tWgfR9Oaw1O70qSGWWHcEdYnWQHJb75MYZlOOxDV3ug22nJ4LtoPCjeVZNbEWjsGyMg/M275t2Tk55znPNNvfBui3+pyahLDcw3M2DO1pfT26z4GB5ixuqycDHzA8cdK2LW1gsbSK1s4UgghQJHFGu1UUcAAdhTl70Wn1/4P+egLR3R5p4L8Oa1oWlaWdX0PUL690sMrNcXluwaR+GkgVGVcEsWLy4kxuHzFjUWsw654W8GeK7JNPVpdWuibKa2ZF3zXe1DGozksrs3zNtGMHPUD1WsjXPC+l+IprOTVVumayk82DyL6eAI/ZsRuoJHYnOMn1NDd3r8/S+oLTb1+fQ4fU/B2ta9obf2fZHw9/ZukTWOj2Ukse9ZZFCtI5jZlX5V2rhj94k46VFJ4R1i68HTWsGj3cN5PYx6X5moXcDTwxO6rL5axHyUQJk/LhmIXI4FeqUUXu9f63/zYlpa3T/gf5HJ+ItDuV0nQdI0LTzLYW17C08ayqgSKIF0yWOceYsecBjjPBrnrbwlrT+KteGr2dzf22o6gtzFJJdRLZeUAoVXRf3zMoH3CDGcdRk16bRRd3v/AF0/yCytb+uv+Z53L4T1L7FJK1g093rGuLdagv2lR5NvG+YlznG3EcQIXJ+ZuDWj4bs9b0rxFr63WjlzqGom5TVPtEZieHCqiFc+YGVRgDbtP94Zrs6KFp/Xp/khvX+vX/P8jzHw14Q1mDU7qLX7K5vP+JxJf/abi6i+yOpcsjJHH+8dwu0ASjCkAg/KBXp1FFLokHVsKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==" alt="" width="753" height="476" vspace="0" hspace="0" border="0" style="width:753px;height:476px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>1 See inflammatory gastrointestinal disorders warning in section 4.4<br />Paediatric population<br />In general, the safety profile for children and adolescents (6 to 18 years of age) is similar to the safety profile for adults.<br /><strong>To report any side effect(s):<br />&bull; Saudi Arabia:</strong><br />The National Pharmacovigilance Centre (NPC):<br />o SFDA call center : 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa/<br />&bull; Sanofi- Pharmacovigilance: KSA_Pharmacovigilance@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no adverse reactions. In CKD patients, the maximum average daily dose studied was 14.4 grams of sevelamer carbonate in a single daily dose.<br />The symptoms observed in case of overdose are similar to adverse reactions listed in section 4.8, including mainly constipation and other known gastrointestinal disorders.<br />Appropriate symptomatic treatment should be provided.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: All other therapeutic products, drugs for treatment of hyperkalemia and</p><p>hyperphosphataemia. ATC code: V03A E02.<br /><u>Mechanism of action</u><br />Renvela contains sevelamer, a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. Sevelamer contains multiple amines separated by one carbon from the polymer backbone which become protonated in the stomach. These protonated amines bind negatively charged ions such as dietary phosphate in the intestine.<br /><u>Pharmacodynamic effect</u><br />By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer lowers the phosphorus concentration in the serum. Regular monitoring of serum phosphorus levels is always necessary during phosphate binder administration.<br /><u>Clinical efficacy and safety</u><br />In two randomised, cross over clinical trials, sevelamer carbonate in both tablet and powder formulations when administered three times per day has been shown to be therapeutically equivalent to sevelamer hydrochloride and therefore effective in controlling serum phosphorus in CKD patients on haemodialysis.<br />The first study demonstrated that sevelamer carbonate tablets dosed three times per day was equivalent to sevelamer hydrochloride tablets dosed three times per day in 79 haemodialysis patients treated over two randomised 8 week treatment periods (mean serum phosphorus time-weighted averages were<br />1.5 &plusmn; 0.3 mmol/l for both sevelamer carbonate and sevelamer hydrochloride). The second study demonstrated that sevelamer carbonate powder dosed three times per day was equivalent to sevelamer hydrochloride tablets dosed three times per day in 31 hyperphosphataemic (defined as serum phosphorus levels &ge; 1.78 mmol/l) haemodialysis patients over two randomised 4 week treatment periods (mean serum phosphorus time-weighted averages were 1.6 &plusmn; 0.5 mmol/l for sevelamer carbonate powder and 1.7 &plusmn;<br />0.4 mmol/l for sevelamer hydrochloride tablets).<br />In the clinical trials in haemodialysis patients, sevelamer alone did not have a consistent and clinically significant effect on iPTH. In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate. In patients with secondary hyperparathyroidism sevelamer carbonate should be used within the context of a multiple therapeutic approach, which could include calcium as supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the iPTH levels.<br />Sevelamer has been shown to bind bile acids in vitro and in vivo in experimental animal models. Bile acid binding by ion exchange resins is a well-established method of lowering blood cholesterol. In clinical trials of sevelamer, both the mean total-cholesterol and LDL-cholesterol declined by 15-39%. The decrease in cholesterol has been observed after 2 weeks of treatment and is maintained with long-term treatment.<br />Triglycerides, HDL-cholesterol and albumin levels did not change following sevelamer treatment.<br />Because sevelamer binds bile acids, it may interfere with the absorption of fat soluble vitamins such as A, D, E and K.<br />Sevelamer does not contain calcium and decreases the incidence of hypercalcaemic episodes as compared to patients using calcium based phosphate binders alone. The effects of sevelamer on phosphorus and calcium were proven to be maintained throughout a study with one year follow-up. This information was obtained from studies in which sevelamer hydrochloride was used.<br /><u>Paediatric population</u><br />The safety and effectiveness of sevelamer carbonate in hyperphosphatemic paediatric patients with CKD was evaluated in a multicenter study with a 2-week, randomised, placebo-controlled, fixed dose period (FDP) followed by a 6-month, single-arm, open-label, dose titration period (DTP). A total of 101 patients (6 to 18 years old with a BSA range of 0.8 m2 to 2.4 m2) were randomised in the study. Forty-nine (49) patients&nbsp;received sevelamer carbonate and 51 received placebo during the 2 week FDP. Thereafter all patients received sevelamer carbonate for the 26-week DTP. The study met its primary endpoint, meaning Sevelamer carbonate reduced serum phosphorus by an LS mean difference of 0.90 mg/dL compared to placebo, and secondary efficacy endpoints. In paediatric patients with hyperphosphatemia secondary to CKD, sevelamer carbonate significantly reduced serum phosphorus levels compared to placebo during a 2-week FDP. The treatment response was maintained in the paediatric patients who received sevelamer carbonate during the 6- month open-label DTP. 27% of paediatric patients reached their age appropriate serum phosphorus level at end of treatment. These figures were 23% and 15% in the subgroup of patients on hemodialysis and peritoneal dialysis, respectively. The treatment response during the 2-week FDP was not affected by BSA, in contrast however, no treatment response was observed in paediatric patients with qualifying phosphorus levels &lt;7.0 mg/dL. Most of adverse events reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature. No new risks or safety signals were identified with the use of sevelamer carbonate during the study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic studies have not been carried out with sevelamer carbonate. Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, is not absorbed from the gastrointestinal tract, as confirmed by an absorption study in healthy volunteers.<br />In a clinical trial of one year, no evidence of accumulation of sevelamer was seen. However the potential absorption and accumulation of sevelamer during long-term chronic treatment (&gt; one year) cannot be totally excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data with sevelamer reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity.<br />Carcinogenicity studies with oral sevelamer hydrochloride were conducted in mice (doses of up to<br />9 g/kg/day) and rats (0.3, 1, or 3 g/kg/day). There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high dose group (human equivalent dose twice the maximum clinical trial dose of 14.4 g). There was no increased incidence of tumours observed in mice (human equivalent dose<br />3 times the maximum clinical trial dose).<br />In an in vitro mammalian cytogenetic test with metabolic activation, sevelamer hydrochloride caused a statistically significant increase in the number of structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in the Ames bacterial mutation assay.<br />In rats and dogs, sevelamer reduced absorption of fat soluble vitamins D, E and K (coagulation factors), and folic acid.<br />Deficits in skeletal ossification were observed in several locations in foetuses of female rats dosed with sevelamer at intermediate and high doses (human equivalent dose less than the maximum clinical trial dose of 14.4 g). The effects may be secondary to vitamin D depletion.<br />In pregnant rabbits given oral doses of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose twice the maximum clinical trial dose).<br />Sevelamer hydrochloride did not impair the fertility of male or female rats in a dietary administration study in which the females were treated from 14 days prior to mating through gestation and the males were treated for 28 days prior to mating. The highest dose in this study was 4.5 g/kg/day (human equivalent dose 2 times the maximum clinical trial dose of 13 g/day, based on a comparison of relative BSA).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />Microcrystalline cellulose Sodium chloride<br />Zinc stearate<br />Film-coating:<br />Hypromellose (E464) Diacetylated monoglycerides<br />Printing ink:<br />Iron oxide black (E172) Propylene glycol Isopropyl alcohol Hypromellose (E464)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the bottle tightly closed in order to protect from moisture.<br />Store Below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottles with a polypropylene cap and a foil induction seal. Each bottle contains 30 tablets or 180 tablets.<br />Packs of 1 bottle of 30 or 180 tablets (without outer carton) and a multipack containing 180 (6 bottles of 30) tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Genzyme Europe B.V. Paasheuvelweg 25
1105 BP Amsterdam The Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JAN 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>